




CHARACTERIZATION OF THE FUNCTION OF TIGHT 
















INSTITUTE OF MOLECULAR AND CELL BIOLOGY 







I would like to express my special thanks to my supervisor, A/P Walter Hunziker, for his 
patient guidance and encouragement throughout my study. I also wish to thank my 
supervisory committee members, Prof. Ito Yoshiaki and Asst. Prof. Li Baojie, for their 
invaluable advice and the time spent on my postgraduate committee meetings every year. 
I thank Dr. Zakir Hossain for his help during the initial stages of my project, Dr. Ke Guo 
for her help on the histological analysis, and Mr. Chee Peng Ng for his support with the 
















TABLE OF CONTENTS 
 
LIST OF FIGURES----------------------------------------------------------------------------------6 
LIST OF TABLES-----------------------------------------------------------------------------------8 
LIST OF VIDEO-------------------------------------------------------------------------------------9 
ABBREVIATIONS--------------------------------------------------------------------------------10 
ABSTRACT-----------------------------------------------------------------------------------------11 
CHAPTER 1: INTRODUCTION----------------------------------------------------------------12 
1.1: Tight junctions (TJs) -------------------------------------------------------------------------14 
1.1.1: Structure and function of TJs -------------------------------------------------------------14 
1.1.2 TJ proteins------------------------------------------------------------------------------------16 
1.1.3 TJ modulation-------------------- ------------------------------------------------------------18 
1.2 MAGUK proteins------------------------------------------------------------------------------18 
1.3 ZO proteins--------------------------------------------------------------------------------------20 
1.3.1 ZO-1-------------------------------------------------------------------------------------------20 
1.3.1.1 Molecular structure of ZO-1-------------------------------------------------------------20 
1.3.1.2 Expression pattern of ZO-1--------------------------------------------------------------21 
1.3.1.3 Expression pattern of ZO-1 isoforms---------------------------------------------------22 
1.3.1.4 Interaction partners------------------------------------------------------------------------24 
1.3.1.5 ZO-1 functions, regulation and associated diseases-----------------------------------30 
1.3.2 ZO-2-------------------------------------------------------------------------------------------34 
1.3.2.1 Molecular structure of ZO-2-------------------------------------------------------------34 
1.3.2.2 Interaction partners of ZO-2-------------------------------------------------------------35 
1.3.2.3 ZO-2 and associated diseases------------------------------------------------------------36 
1.3.3 ZO-3-------------------------------------------------------------------------------------------37 
1.3.3.1 Molecular structure of ZO-3-------------------------------------------------------------37 
1.3.3.2 Interaction partners of ZO-3-------------------------------------------------------------38 
1.3.3.3 Functions of ZO-3-------------------------------------------------------------------------39 
1.4 Rationale and aim of research----------------------------------------------------------------40 
Chapter 2: Materials and methods----------------------------------------------------------------42 
Chapter 3: Generation and phenotypic analysis of ZO-1 chimeric mice and embryos----51 
3.1 Generation of ZO-1-/+ and -/- ES cells------------------------------------------------------51 
3.2 ZO-1 chimeric mice----------------------------------------------------------------------------54 
3.3 Discussion---------------------------------------------------------------------------------------55 
Chapter 4: Generation and phenotypic analysis of ZO-2 null mice--------------------------56 
4.1 Generation of ZO-2-/+ ES cells--------------------------------------------------------------56 
4.2 Generation of ZO-2-/- mice-------------------------------------------------------------------58 
4.3 Embryonic lethality for ZO-2-/- mice-------------------------------------------------------58 
4.4 Decreased cell proliferation in ZO-2-/- embryos------------------------------------------61 
4.5 Increased apoptosis in E7.5 ZO-2-/- embryos----------------------------------------------62 
4.6 ZO-2-/- embryos lack mesoderm-------------------------------------------------------------63 
4.7 Expression and localization of TJ and adherens junction (AJ) markers is not affected 
in ZO-2-/- embryos---------------------------------------------------------------------------------64 
4.8 The TJ architecture is altered in ZO-2-/- embryos-----------------------------------------66 
4.9 The function of TJs as a diffusion barrier is affected in ZO-2-/- embryos-------------66 
 4
4.10 ZO-2-/- blastocysts grow normally in vitro-----------------------------------------------69 
4.11 Discussion-------------------------------------------------------------------------------------71 
Chapter 5: ZO-2 rescue and phenotypic analysis----------------------------------------------72 
5.1 Expression pattern of ZO-2 in early embryo development stage------------------------72 
5.2 Generation of ZO-2 chimeric embryos------------------------------------------------------74 
5.3 ZO-2 is dispensable for epiblast development---------------------------------------------75 
5.4 Chimeric expression of ZO-2-/- cells in testis results in reduced fertility of male 
chimeric mice----------------------------------------------------------------------------------------77 
5.5 Chimeric expression of ZO-2-/- cells in the testis results in apoptosis -----------------79 
5.6 ZO-2 chimeric mice present with defects in balance and hearing-----------------------82 
5.7 Defects in other organs of ZO-2 chimeric mice--------------------------------------------83 
5.8 Disscusion---------------------------------------------------------------------------------------84 
Chapter 6: Generation and phenotypic analysis of ZO-3-/- mice ----------------------------86 
6.1 Generation of ZO-3-/- mice-------------------------------------------------------------------86 
6.2 ZO-3-/- mice are born and viable------------------------------------------------------------89 
6.3 Organs of ZO-3-/- mice are histologically normal-----------------------------------------91 
6.4 Expression and localization of TJ and AJ markers are unaffected in the small intestine 
of ZO-3-/- mice-------------------------------------------------------------------------------------92 
6.5 TJ architecture is intact in ZO-3 null mice-------------------------------------------------94 
6.6 ZO-3 deficiency does not affect mouse growth-------------------------------------------95 
6.7 Discussion--------------------------------------------------------------------------------------96 
Chapter 7: Generation and phenotypic analysis of ZO-2-/-ZO-3-/- mice ------------------97 
7.1 Generation of ZO-2-/- ZO-3-/- mice--------------------------------------------------------97 
7.2 ZO-2-/+ZO-3 -/- mice are histologically normal------------------------------------------98 
7.3 ZO-2-/-ZO-3-/- embryos die earlier than ZO-2-/- embryos-----------------------------100 
7.4 ZO-2-/- ZO-3-/- blastocysts grow normally in vitro-------------------------------------101 
7.5 Discussion-------------------------------------------------------------------------------------103 
Chapter 8: Phenotypic analysis of ZO-1-/- embryonic stem cells--------------------------105 
8.1 Protein expression in ZO-1-/- EBs---------------------------------------------------------105 
8.2 The subcellular localization of several TJ and AJ markers is altered in ZO-1-/- EBs--- 
-------------------------------------------------------------------------------------------------------107 
8.3 The TJ structure is affected in ZO-1-/- EBs-----------------------------------------------114 
8.4 ZO-1 deficiency promotes mesoderm development-------------------------------------116 
8.5 ZO-1deficiency promotes mesoderm development via aβ–catenin/Wnt dependent 
signaling pathway---------------------------------------------------------------------------------116 
8.6 EBs derived from ZO-1-/- ES cells have a larger volume compared to ZO-1+/+ EBs--
-------------------------------------------------------------------------------------------------------119 
8.7 Discussion-------------------------------------------------------------------------------------122 
Chapter 9: Generation and phenotypic analysis of ZO-2-/- embryonic stem cells-------125 
9.1 Generation of ZO-2-/- ES cells-------------------------------------------------------------125 
9.2 Normal expression levels of TJ and AJ markers in ZO-2-/- EBs----------------------127 
9.3 Normal localization of selected TJ and AJ markers in epithelia of ZO-2-/- EBs----129 
9.4 The TJ structure and function are unaffected in ZO-2-/- EBs--------------------------133 
9.5 ZO-2-/- EBs are larger as compared to that of ZO-2+/+ EBs---------------------------135 
9.6 Discussion-------------------------------------------------------------------------------------137 
Chapter 10: Generation and phenotypic analysis of ZO-1-/-ZO-2-/- ES cells -----------139 
 5
10.1 Generation of ZO-1-/-ZO-2-/- ES cells---------------------------------------------------139 
10.2 Protein expression in ZO-1-/-ZO-2-/- EBs-----------------------------------------------141 
10.3 The volume of ZO-1-/-ZO-2-/- EBs is larger as compared to that of WT EBs-----142 
10.4 ZO-1/ZO-2 double knockout affects cell attachment and migration-----------------144 
10.5 Discussion------------------------------------------------------------------------------------147 
Chapter 11: Generation and phenotypic analysis of ZO-2-/-ZO-3-/- embryonic stem cells 
-------------------------------------------------------------------------------------------------------148 
11.1 Isolation of ZO-3-/- ES cells---------------------------------------------------------------148 
11.2 Generation of ZO-2-/-ZO-3-/- ES cells---------------------------------------------------151 
11.3 The expression levels of TJ and AJ markers are not altered in ZO-2-/-ZO-3-/- EBs---
-------------------------------------------------------------------------------------------------------153 
11.4 The localization of TJ and AJ markers is not altered in ZO-2-/-ZO-3-/- EBs-------154 
11.5 Discussion------------------------------------------------------------------------------------157 


































LIST OF FIGURES 
 
Figure 1 Schematic drawing of three types of basic epithelial tissues in different organs. 
Figure 2 Location and structure of TJs. 
Figure 3 Schematic drawing of the TJ proteins. 
Figure 4 Schematic structures of the MAGUK proteins, ZO-1, ZO-2 and ZO-3. 
Figure 5 Targeting of ZO-1 locus and PCR screening. 
Figure 6 Characterization of ZO-1-/- ES cell lines. 
Figure 7 ZO-1 chimeric mice are embryonic lethal. 
Figure 8 Targeting of the ZO-2 gene. 
Figure 9 Genotyping of transgenic mice. 
Figure 10 Developmental arrest of ZO-2-/- embryos. 
Figure 11 Postimplantation development of ZO-2-/- embryos. 
Figure 12 Cell proliferation is compromised in E6.5 ZO-2-/- embryos. 
Figure 13 Enhanced apoptosis in E7.5 ZO-2-/- embryos. 
Figure 14 T-gene expressions in E7.5 ZO-2-/- embryos and EBs. 
Figure 15 Distribution of ZO-1and ZO-3 in ZO-2-/- embryos is not altered. 
Figure 16 Apical-basal polarity is not affected in ZO-2-/- embryos. 
Figure 17 The architecture of the apical junctional complex is altered in cells of ZO-2-/- 
embryos. 
Figure 18 The permeability barrier of the apical junctional complex is altered in cells of 
ZO-2-/- embryos. 
Figure 19 In vitro blastocyst culture and PCR genotyping. 
Figure 20 ZO-2 expression in early stage embryos. 
Figure 21 Expression of ZO-2 in the skin of E15.5 embryos. 
Figure 22 Expression of ZO proteins in chimeric mice. 
Figure 23 Histological analysis of the testis. 
Figure 24 Apoptosis in the testis of ZO-2 chimeric mice. 
Figure 25 ZO-2 and ZO-1 expression in testis 
Figure 26 Targeting of the ZO-3 
Figure 27 Genotyping of transgenic mice. 
Figure 28 Western blot detection of ZO-3 protein. 
Figure 29 ZO-3 expressions in major mouse organ. 
Figure 30 H&E staining of small intestine of ZO-3-/- and ZO-3+/+ mice. 
Figure 31 Protein distributions in small intestine. 
Figure 32 TJ morphology 
Figure 33 Postnatal growth curves of ZO-3-/- and ZO-3+/+ mice. 
Figure 34 Histological analysis of ZO-2-/+ZO-3-/- mice 
Figure 35 Western blots for ZO protein expression. 
Figure 36 Histological analysis of ZO-2-/-ZO-3-/- embryos. 
Figure 37 In vitro culture of blastocysts. 
Figure 38 Statistical analysis of the number blastocysts in different genotype. 
Figure 39 Expression levels of selected junction-associated proteins in ZO-1-/- EBs. 
Figure 40 Distribution of ZO proteins, TJ and AJ markers in ZO-1-/- EBs. 
Figure 41 Apico-basolateral polarities are not affected in ZO-1-/- EBs. 
 7
Figure 42 The architecture of the apical junctional complex is altered in cells of ZO-1-/- 
EBs. 
Figure 43 ZO-1 deficiency results in the upregulation of T-gene expression. 
Figure 44 Proliferation of ZO-1-/- EBs. 
Figure 45 Generation of ZO-1 -/- ES cell lines. 
Figure 46 Protein expressions in ZO-2-/- EBs 
Figure 47 Distribution of ZO proteins and selected TJ and AJ markers in ZO-2-/- EBs. 
Figure 48 The apico-basolateral polarity is not affected in ZO-2-/- EBs. 
Figure 49 The architecture and permeability barrier of the apical junctional complex are 
not altered in cells of ZO-2 -/- EBs. 
Figure 50 Volume of ZO-2-/- EBs. 
Figure 51 Characterization of ZO-1-/-ZO-2-/- ES cells. 
Figure 52 Protein expressions in ZO-1-/-ZO-2-/- EBs. 
Figure 53 Morphology and cell growth curve of ZO-1-/-ZO-2-/- EBs. 
Figure 54 Morphology of EBs after 2 days and 5 days culture on normal cell culture 
plates.  
Figure 55 Scanning electron microscopy of day (2+5) cultured EBs 
Figure 56 Expression levels of ZO proteins and TJ and AJ markers in ZO-3-/- EBs. 
Figure 57 ZO protein expressions in ZO-3-/- EBs. 
Figure 58 Characterization of ZO-2-/-ZO-3-/- ES cells 
Figure 59 Expression levels of ZO proteins and TJ and AJ markers ZO-2-/-ZO-3-/- EBs. 
Figure 60 Distribution of ZO proteins, TJ and AJ markers in ZO-2-/-ZO-3 EBs. 
























LIST OF TABLES 
 
Table 1 Genotypic analysis of offspring and embryos from crossing of ZO-2-/+ mice 
Table 2 Statistical analysis of the frequency of TJs with altered structure in ZO-2-/- and 
ZO-2+/+ embryos 
Table 3 Statistical analysis of the fraction of leaky TJs in ZO-2+/+ and ZO-2-/- embryos. 
Table 4 Rescue of embryonic lethality by injecting ZO-2-/- ES cell into WT blastocysts 
Table 5 Cross between chimeric mice and C57BL/6 WT mice. 
Table 6 Cross between different types of male mice with C57BL/6 female mice. 
Table 7 Balance defect in ZO-2 chimeric mice 
Table 8 Prayer Reflex analysis for hearing 
Table 9 Genotypic analysis of offspring from ZO-3-/+ mice crossing 
Table 10 Cross between ZO-2-/+ZO-3-/- mice does not yield any ZO-2-/-ZO-3-/- mice.  
Table 11 Statistical analysis of embryo morphology (normal or small and undergoing 
absorption) at E6.5 and E7.5 































LIST OF VIDEOS 
 












































a.a.: amino acid 
AJ: adherens junction 
AMP: adenosine monophosphate 
ATP: adenosine triphosphate 
BBB: blood-brain barrier 
BrdU: bromodeoxyuridine 
CIS: carcinoma in situ 
CRC: primary colorectal cancer 
CX: Connexin 
EB: embryoid body 
EGFR: epidermal growth factor receptor 
EMT: epithelial-mesenchymal transition 
ES: embryonic stem 
FHC: familial hypercholanemia 
GUK: guanylate-like 
GMP: guanosine monophosphate 
JAM: junctional adhesion molecule 
kDa: kiloDalton 
MAGUK: membrane-associated guanylate kinase homolog 
MDCK: Madin-Darby Canine Kidney 
NES: nuclear export signal 
NLS: nuclear localization signal 
PATJ: PALS1-associated TJ protein 
PKC: protein kinase C 
PDZ: PSD-95, Dlg, ZO-1 
SAF-B: scaffold attachment factor-B 
SH3: Src homology 3 
TER: transepithelial electrical resistance 
TM: transmembrane 
TJ: tight junction 
ZO: Zonula Occludens 
ZO-1: Zonula Occludens-1 
ZO-2: Zonula Occludens-2 
ZO-3: Zonula Occludens-3 











ZO-1, ZO-2 and ZO-3 are closely related scaffolding proteins that link tight 
junction (TJ) transmembrane proteins such as occludin, claudins and junctional adhesion 
molecules to the actin cytoskeleton. Despite being among the first TJ proteins to have 
been identified and having undergone extensive biochemical analysis, little is know about 
the physiological roles of individual ZO proteins in different tissues or during vertebrate 
development. Here, we show that ZO-3-/- mice lack an obvious phenotype. In contrast, 
embryos deficient for ZO-2 die shortly after implantation due to an arrest in early 
gastrulation. ZO-2-/- embryos show decreased proliferation at E6.5, increased apoptosis 
at E7.5 and altered architecture of the apical junctional complex as compared to wild-type. 
ZO-1-/- mice are currently unavailable, while chimeric mice derived from ZO-1-/- 
embryonic stem (ES) cells are embryonic lethal. Because of the embryonic lethality of 
the ZO-1-/- and ZO-2-/- mice, we also generated knockout ES cell lines. We have 
obtained ZO-1-/-, ZO-2-/-, ZO-3-/-, ZO-1-/-ZO-2-/-, and ZO-2-/-ZO-3-/- ES cells. These 
cell lines have shown various defects in their ability to differentiate into epithelial cells, 














Chapter 1 Introduction 
Multicellular organisms are separated from the external environment by a layer of 
epithelial cells, which also line the internal cavities and ducts of tissues and organs. 
Epithelial tissues can be grouped into three basic types: squamous (such as skin, the 
linings of the peritoneum and the epidermis), cuboidal (such as the the epithelium 
forming the collecting duct of the kidney), and columnar (such as that lining the small 
intestine) (Figure 1). Two pathways are available for the transepithelial transport of 
molecules. The first one is the transcellular pathway that requires the solutes to be 
internalized to cross the epithelial cells. The second one is the paracellular pathway, 
where solutes pass the paracellular barrier. Establishment of a paracellular barrier with 
controlled permeability between the epithelial cells is important for the maintenance of a 
specific internal environment that is crucial for the development and survival of 
multicellular organisms. The epithelial cell layer is closely joined by membrane 
structures named tight junctions (TJs), which play a role in allowing different tissue or 
organ compartments to maintain different solute composition without, however, 
completely obstructing the exchange of solutes between bordering compartments. The 
permeability of TJ barrier is controlled by both internal (for example, cyclic AMP and 
RhoA) and external signals (for example, zonulin antagonists and agonists), and thus can 
be modulated under certain circumstances (for example, in the process EMT during 
differentiation). Modulation of the TJ barrier is also of clinical interest for drug delivery. 
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Figure 1 Three types of basic epithelial tissues in different organs. 
 Stratified squamous epithelia form the skin; simple cuboidal epithelia line the collecting 






















1.1 Tight junctions 
1.1.1 Structure and function of TJs  
TJs locate at the most apical side of two adjacent epithelial or endothelial cells 
(Figure 2A). In a freeze-fracture, TJs appear as strands (Figure 2B). These strands, 
derived from the two adjacent cells, form a series of fusion points, which surround each 
cell on the most apical side and thus obliterate the intercellular space (Figure 2 C, D). The 
major function of TJs is to seal the paracellular pathway and block the diffusion of 
solutes between the external (luminal) and the internal (serosal) space. Claudins, a protein 
family with over 20 members in mammals, are thought to form the charge-selective pores 
in the TJ barriers. If the net charge of the pores is negative, the cations are allowed to 
pass the TJ barriers (Sasaki et al., 2003). Since non-charged solutes are not affected by 
the net charge in the claudins pores, they are thought to cross the TJ barriers via a 
different mechanism. TJ strands are able to dynamically break and reseal and non-
charged solutes can cross TJs through the temporal gaps during this dynamic process 
(Sasaki et al., 2003). The permeability of TJs varies in different tissues depending on the 
functions they performed, and this is thought to reflect different claudin repertoires. For 
example, the urinary bladder and the stomach duct can have a transepithelial electrical 
resistance (TER) up to a few thousand Ω cm2, while the small intestine has a TER of a 
few Ω cm2. The TJ permeability is not always the same even in the same organ. For 
example, paracellular transport across renal tubular epithelial TJs varies in different 
segments of the nephron.  
 TJs also function as a fence between apical and basolateral membrane domains to 
block protein and lipid diffusion within the plasma membrane and maintain cell polarity. 
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In addition to being a permeability barrier and a fence, TJs also act as a multifunctional 
complex that regulates various cellular functions such as membrane trafficking (exocyst, 
rab13), signal transduction (cell density, ZO-1), tumor suppression (suppression of Ad9 
E4-ORF1-induced focus formation, ZO-2), cell proliferation (ZONAB). In addtion, TJs 
often serve as entry points for the infection by different pathogens (adenovirus, ZO-2). 
 
Figure 2 Location and structure of TJs. (A) The TJ (circled) is located at the most 
apical region of lateral membranes. (B) Freeze-fracture image shows the the strands 
(arrowheads) and grooves (arrows) of TJs. (C) Ultrathin sectional view demonstrates 
that kissiong points (arrowheads) obliterate the intercellular space in TJs. (D) Schematic 
drawing of the TJs. (Tsukita  et al., 2001) Mv, microvilli; TJ, tight junction; AJ, adherens 
junction; DS, desmosome; AP, apical membrane; Bl, basalateral membrane 
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1.1.2 TJ proteins 
In TJs, transmembrane (TM) proteins that interact with corresponding proteins on 
the adjacent membranes are tethered to the actin cytoskeleton via scaffolding proteins 
(Figure 3). The TM proteins are integrated in the plasma membrane and may be able to 
transduce extracellular signals, for example in response to cell-cell contact, into the cells. 
The scaffolding or plaque proteins locate on the cytoplasmic surface of the plasma 
membrane (Figure 3). They link the integral proteins with the actin cytoskeleton. Some 
plaque proteins are also involved in vesicular trafficking, nuclear shuttling, control of 
gene expression and infection of viruses and bacteria. The structure and function of 
selected integral and plaque proteins of TJs are discussed in more detail below. 
 
Figure 3 Schematic drawing of the TJ proteins. TJ proteins consist of TM proteins and 




TM proteins of TJ 
The three most common TM proteins of TJs are occludin, claudins, and junctional 
adhesion molecules (JAMs) (Figure 3). Both occludin and claudins have four TM regions 
and two extracellular domains. Their C- and N-terminal ends reside in the cytoplasm. 
Occludin is encoded by a single gene, while claudins form a large gene family of more 
than twenty members in mammals. Occludin and claudins form the backbone of the TJ 
strands. The combination of occludin and different members of claudins is thought to 
determine the tightness of the TJs. In contrast to occludin and claudins, JAMs have only 
one TM domain, with the C-terminal end locating outside the cell and the short N-
terminal tail residing inside the cytosplasm. JAMs mainly function in immune response, 
involving trafficking of T-lymphocytes, neutrophiles and dentritic cells. 
Plaque proteins of TJs  
Plaque proteins locate under the plasma membrane and function as scaffolds to link 
the TM proteins to the actin cytoskeleton (Figure 3). Plaque proteins can be grouped into 
two types based on the presence (for example the ZO proteins) or absence (for example 
cingulin) of one or multiple PDZ domains (González-Mariscal et al., 2007; Guillemot et 
al., 2008). The PDZ domain is a short module of 80-90 amino acids, capable of binding 
small C-terminal peptide motifs or other PDZ domains. Thus, PDZ domain proteins can 
function as scaffolds to bring together integral, signaling and cytoskeleton proteins. Some 
scaffolding TJ proteins lacking PDZ domains such as cingulin can also link integral 
proteins to the actin cytoskeleton, whereas other function in vesicular trafficking and 
other cellular processes.  
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1.1.3 TJ modulation 
The structure and function of TJs is dynamically regulated and this regulation is 
fundamental to many physiological processes in multicellular organisms. Many cytokines 
have been shown to modulate TJ function through their effects on TJ proteins and the 
associated actin cytoskeleton (Walsh et al., 2000). Small GTPases form a large family of 
signal transduction molecules. They control cell-cell contact and regulate parecellular 
permeability through G protein-coupled events (Hopkins et al., 2000). In addition to 
cytokines and small GTPases, protein kinase C (PKC) also plays a role in the regulation 
of TJs. PKC activation dramatically increases TJ permeability and the increased leakiness 
correlates with tumor promotion in epithelial cancers (Mullin et al., 2000). Specific TJ 
modulation is also of interest for therapeutic drug delivery. Drugs can cross membranes 
by transcellular or paracellular pathway and the paracellular pathway is controlled by TJs. 
Temporal opening of the TJs may be a promising approach for delivering therapeutic 
agents (for example across the intestinal barrier) to the systemic circulation and finally to 
the site of action (for example across the BBB to target the brain) (Salama  et al., 2006). 
1.2 MAGUK proteins 
ZO-1, ZO-2 and ZO-3 are TJ associated scaffold proteins belonging to the MAGUK 
(membrane-associated guanylate kinase homologs) protein family. The MAGUK proteins 
are a family of proteins that locate to various junctional complexes, including TJs in the 
epithelial and endothelial cells, as well as synaptic and neuromuscular junctions. They are 
required for the formation of various cell junctions since loss of particular MAGUK 
members may result in disruption of specific junctional complexes. For example, 
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combined ZO-1 knockout and ZO-2 knockdown completely blocks TJ formation in 
epithelial cells (Umeda  et al., 2006) 
All MAGUK proteins have three PDZ domains, one Src homology 3 (SH3) and one 
guanylatekinase-like (GUK) domain (Figure 4). As discribed above, PDZ domains bind 
short C-terminal peptides or other PDZ domains. SH3 domains usually consist of 50-70 
amino acids and bind ligands containing PXXP sequences or, in the case of MAGUKs, 
the GUK domain. The GUK domain is homologous to the enzyme guanylate kinase, 
which can catalyze the GMP at the expense of ATP. However, the GUK domain in 
MAGUKs can bind neither GMP nor ATP and is thus most likely enzymatically inactive.  
 
Figure 4 Schematic structures of the MAGUK proteins, ZO-1, ZO-2 and ZO-3. All 
three members have three PDZ domains, one SH3 and one GUK domain, one C-terminal 
acidic region. ZO-1 and ZO-2 have a Proline-rich region in the C-terminus, while the 
Proline-rich region of ZO-3 is located between the second and third PDZ domain 
(Kausalya PJ 2005).  
 
 
MAGUK proteins bind directly to the C-terminal portion of the TM proteins as well 
as other signal transduction proteins and, in some cases, to actin. They function as 
molecular platforms to assemble and regulate signaling pathways at the plasma 
membrane and couple various extracellular signals with intracellular signal transduction 
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pathways. They also work as molecular scaffolds to maintain the structural specialization 
of plasma membrane domains.  
MAGUK proteins regulate the polarity of epithelial cells. Multi-domain scaffolding 
proteins of the MAGUK family are widely expressed at the plasma membrane of the 
polarized epithelial cells, where they participate in junction assembly, recruitment of 
proteins to specific plasma membrane domains, the organization of polarized signaling 
complexes and the maintenance of asymmetric proteins distributions, thus controlling 
important features of cell polarity (Caruana  et al., 2002). 
Some MAGUK proteins can also shuttle between TJs and nucleus, where they might 
be involved in the regulation of gene expression (González-Mariscal  et al., 2000). 
1.3 ZO proteins 
1.3.1 ZO-1 
1.3.1.1 Molecular structure of ZO-1 
ZO-1 was the first protein shown to associate with TJs (Stevenson et al., 1986). It 
has a molecular weight of 225 kDa in mouse tissues and 210 kDa in MDCK cells 
(Anderson et al., 1988). The human ZO-1 is predicted to have 1763 amino acids, with the 
N-terminal 793 amino acids homologous to the Drosophila discs-large tumor suppressor 
protein of septate junctions and to PSD95, a postsynaptic density protein of 95 kDa 
(Willott et al., 1993). Typical for a MAGUK family member, ZO-1 has three PDZ 
domains, followed by one SH3 domain and one GUK domain. In addition, ZO-1 carries 
one proline-rich domain at its C-terminus (Figure 4). ZO-1 has two nuclear localization 
signals (NLS), one located in the first PDZ domain and the other in the GUK domain 
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(González-Mariscal et al., 1999). ZO-1 localizes to TJs but in some cases has been 
reported to be present in the nucleus in sparse cell cultures (Gottardi et al. 1996). In the 
proline-rich domain, ZO-1 contains splicing variants, namely alpha, beta and gamma 
(Willott et al. 1992; González-Mariscal et al. 1999). ZO-1 has two variable regions, U5 
and U6. U5 locates between the SH3 and GUK domain and U6 is immediately after the 
C-terminal of the GUK domain. In cultured cells, ZO-1 protein lacking U5 can not 
localize to TJs, while the lack of U6 will localize ZO-1 protein to the lateral membrane, 
followed by subsequent recruitment of occludin and claudins. These data indicate that the 
SH3-U5-GUK-U6 region is important for protein interactions, and also for signaling 
(Fanning et al. 2007). 
1.3.1.2 Expression pattern of ZO-1 
ZO-1 is expressed as early as in the 8-cell stage of the mouse embryo and initially 
emerges as a series of punctate sites between apposed cells that subsequently punctate 
and merge to form a linear belt around blastocyst trophectoderm cells. ZO-1 expression is 
delayed after inhibition of cell adhesion at the 8-cell stage and its localization is disturbed 
after microfilament disruption, suggesting that ZO-1 expression is dependent on cell 
adhesion and cytoskeleton activity (Fleming et al., 1989, 1991).  
In adult tissues, ZO-1 is expressed in various epithelia and its expression level varies 
depending on the particular tissue. For example, in kidney epithelium ZO-1 expression is 
highest in glomerular epithelium and lowest in the proximal tubule (Schnabel et al., 
1990). In addition to epithelia, ZO-1 is also expressed in endothelial cells and its 
expression level correlates with the cell confluence. ZO-1 expression is low in sparse cell 
culture and its expression level is increased when the culture becomes confluent (Li  et al., 
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1990). Beides epithelial and endothelial cells, ZO-1 is also expressed in several non-
epithelial cell types that may or may not have typical TJs. For example, in astrocytes, 
ZO-1 localizes to the cell-cell contact sites, while in S-180 cells ZO-1 is expressed at the 
cell periphery and within the cytoplasm (Howarth et al., 1992). ZO-1 also distributes to 
the intercalated disc of cardiomyocytes and the apposed membranes of myelinating 
Schwann cells (Toyofuku et al. 1998; Poliak et al., 2002). Furthermore, ZO-1 is a major 
component of the blood-testis barrier. In the testis of newborn mice, ZO-1 locates over 
the apicolateral Sertoli cell membrane. After establishment of TJs, ZO-1 expression is 
restricted to tight junctional regions (Byers et al., 1991). ZO-1 is also detected in human 
and rat BBB. Immunostaining indicates that ZO-1 forms a banded pattern outlining 
individual endothelial cells in blood vessels (Watson  et al., 1991). 
1.3.1.3 Expression pattern of ZO-1 isoforms 
In the ZO-1 cDNA, 240-bp region is subject to alternative splicing. This exon 
encodes an in-frame insertion of 80 amino acids, known as alpha motif. The skipping of 
the corresponding alpha exon depends on two antagonistic exonic elements located in the 
constitutive flanking exons. Depending on the presence or absence of the alpha motif, 
two ZO-1 splice varients, known as ZO-1 alpha+ and ZO-1 alpha- are expressed. Both 
variants are expressed in epithelial cells and localize to the TJs, while their relative 
expression levels vary greatly in different cell lines. These two isoforms form hermetic 
TJs but TJs become leakier when the ZO-1 alpha- is predominantly expessed (Willott et 
al.,1992; Martínez-Contreras et al., 2003). 
The expression pattern of ZO-1 alpha- and alpha+ is different during early embryo 
development. ZO-1 alpha- mRNA is expressed during all pre-implantation stages, while 
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the ZO-1 alpha+ mRNA only appears at the morula stage. These two isoforms also 
function differently in membrane assembly. ZO-1 alpha- initially forms punctuate sites at 
the cell-cell contacts during the 8-cell stage; while ZO-1 alpha+ initially forms 
perinuclear foci during the late morulae stages and joins the membrane assembly only 
around the 32-cell stage. Importantly, ZO-1 alpha+ co-localizes with occludin at the 
perinuclear sites in late morulae stages and at the newly assembled cell junctions. The 
expression of ZO-1 alpha+ and its interaction with occludin might act as a time-limiting 
step in the assembly of TJs and blastocoel formation (Sheth et al., 1997). 
In animal tissues, ZO-1 alpha- is expressed in structurally dynamic junctions such as 
endothelial cells, renal glomeruli and seminiferous tubules. ZO-1 alpha+ is expressed in 
all other epithelial cells that are structurally less dynamic (Balda et al., 1993). Both ZO-1 
alpha+ and ZO-1 alpha- are expressed in typical epithelial TJs of the kidney, while only 
ZO-1 alpha- is expressed in the extremely dynamic structures such as the slit diaphragms, 
where the intercellular spaces are loose, or endothelial junctions that open in response to 
physiologic signals (Kurihara et al., 1992). Both ZO-1 alpha+ and alpha- are also 
expressed in the testis, but their distribution varies in different locations. ZO-1 alpha+ 
localizes to certain TJs that join the Sertoli cells to specific classes of germ cells 
(spermatogonia, preleptotene, and leptotene spermatocytes ), while ZO-1 alpha- is found 
in TJs joining Sertoli cells to all classes of germ cells, suggesting that the expression of 
ZO-1 isoforms might be regulated by specific Sertoli cell-germ cell contacts (Pelletier et 
al., 1997). 
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1.3.1.4 Interaction partners 
Interaction partners of TJs 
The first interaction partner discovered for ZO-1 was ZO-2, which was co-
immunoprecipitated with ZO-1 from MDCK cell lysates (Gumbiner et al., 1991). ZO-1 
also directly interacts with ZO-3 and co-localizes with it at the TJs in MDCK cells 
(Haskins et al., 1998). Immunoprecipitation analysis indicates that the three members of 
the ZO protein family form independent ZO-1/ZO-2 and ZO-1/ZO-3 complexs rather 
than a ZO-1/ZO-2/ZO-3 trimeric complex (Wittchen et al., 1999). In addition to forming 
heterodimers with ZO-2 and ZO-3, ZO-1 can also form homodimers via its second PDZ 
domain. Immunoprecipitation experiments indicate that a substantial fraction of ZO-1 is 
present as homodimers in MDCK cells. ZO-1 homodimers and ZO-1/ZO-2 and ZO-
1/ZO-3 heterodimers might form distinct scaffolds for differnt protein networks 
(Utepbergenov et al., 2006). 
ZO-1 interacts with most types of TM proteins of TJs. Its association with occludin 
is important for membrane localization of occludin (Furuse et al., 1994). The C-terminal 
coil-coil domain of occludin dimerizes and forms a four-helix bundle that interacts with 
ZO-1. The helix bundle of occludin (a.a. 406-521) interacts with the hinge region of ZO-
1 (a.a. 591-632) and ZO-1 (a.a. 726-754) in the GUK domain (Müller et al., 2005). ZO-1 
interacts with claudin-1 to –8. The interaction of claudins with ZO-1 is mediated by the 
C-terminal YV sequence of claudins. When claudin-1 and claudin-2 were transfected into 
L fibroblasts, which only express ZO-1, all the three proteins co-localize to cell-cell 
borders (Itoh et al., 1999). ZO-1 also interacts with the C-terminal TRV sequence of 
Cldn16 (also known as paracellin-1/PCLN-1). Mutation of the TRV motif in Cldn16 that 
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abolishes its interaction with ZO-1, result in a predominantly lysosomal localization 
(Ikari et al., 2004; Muller et al., 2003; Kausalya et al., 2006). ZO-1 can be co-
immunoprecipitated with JAM and the second and third PDZ domains of ZO-1 are 
crucial for the interaction with the C-terminal PDZ-binding motif of JAM. Deletion of the 
PDZ binding domain of JAM not only abolishes its interaction with ZO-1, but also 
disrupts its junctional localization, indicating that ZO-1 plays a role in recruiting or 
retaining JAM to intercellular junctions (Bazzoni et al., 2000; Ebnet et al., 2000). 
ZO-1 also binds to cytosolic TJ plaque proteins. ZO-1 binds to the Ras-binding 
domain of the Ras target AF-6 and this interaction is inhibited by activated Ras. ZO-1 
and AF-6 co-localize at TJs in epithelial cells and at cell-cell adhesion sites in non-
epithelial cells. ZO-1 can be immunoprecipitated by AF-6 from Rat1 cells, indicating that 
ZO-1 interacts with AF-6 in vivo (Yamamoto et al., 1999). Overexpression of activated 
Ras in Rat1 cells interrupts cell-cell contacts and reduces the cell surface accumulation of 
ZO-1 and AF-6, suggesting that ZO-1 may serve as an adapter protein for AF-6 to 
regulate cell-cell contact formation (Yamamoto et al., 1997).  
Another cytosolic TJ protein that ZO-1 interacts with is cingulin (Cordenonsi et al., 
1999). Pull-down analysis shows that the N-terminal ZIM motif of cingulin (1-378) is 
crucial for this interaction. ZO-1 can be immunoprecipitated by cingulin. However, 
cingulin lacking the ZIM motif is still recruited to TJs, indicating that ZO-1 is not the 
only protein that can recruit cingulin. Endogenous ZO-1 localization is disrupted in 
Xenopus A6 cells overexpressing cingulin, suggesting that ZO-1 functionally interacts 
with cingulin in vivo (D'Atri et al., 2002). 
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Interaction partners of adherens junctions (AJs) 
ZO-1 localizes to the cell-cell adhesion sites in non-epithelial cells. The N-terminal 
half of ZO-1 interacts with the E-cadherin/alpha, β-catenin complex, while the C-terminal 
half of ZO-1 binds to actin. Therefore, ZO-1 might serve as a linker between the 
cadherin/catenin complex and the actin cytoskeleton (Itoh et al., 1997). ZO-1 directly 
interacts with alpha-catenin, which binds to ZO-1 in a similar way as occludin. The helix 
bundle of alpha-catenin (a.a. 509-906) interacts with the hinge region of ZO-1 (a.a. 591-
622) and ZO-1 (a.a. 756-781) in the GUK domain (Müller et al., 2005). ZO-1 can bind to 
the C-terminal PDZ-binding motif of ARVCF, which is an armadillo-repeat protein of the 
p120 family. P120 family members interact with E-cadherin and localize to AJs. The 
interaction with ZO-1 may provide an alternative for the recruitment of ARVCF to the 
plasma membrane (Kausalya et al., 2004). 
Interaction partners of gap junctions 
ZO-1 co-localizes with Connexin 43 (Cx43), which plays a critical role in the 
synchronized contraction of cardiomyocytes. The interaction between ZO-1 and Cx43 
occurs via the first PDZ domain of ZO-1 and the C-terminus of Cx43. Overexpression of 
the N-terminal domain of ZO-1 in Cx43-expression cells disrupts the localization of 
Cx43 to the cell-cell interface, concomitant with a loss of electrical coupling. These data 
suggest that ZO-1 may help to recruit Cx43 to the intercalated disc to generate functional 
gap junctions between cardiomyocytes (Toyofuku et al., 1998; Giepmans et al., 2001). 
Both ZO-1 and Cx43 localize to the intercalated discs, but only display moderate co-
localization. However, the degree of co-localization increases significantly after 
enzymatic dissociation of cardiomyocytes from intact ventricles. Co-immunoprecipitation 
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using ZO-1 and Cx43-specific antibodies confirm and increased interaction between ZO-
1 and Cx43 in dissociated as compared to intact ventricles. These data suggest that ZO-1 
might play an important role in gap junction turnover during heart development and 
disease processes (Barker et al., 2002). ZO-1 regulates the function of Cx43 not only in 
cardiomyocytes, but also in other cell types. When Sertoli cells were treated with gamma-
hexachlorocyclohexane (HCH), which induces gap junction endocytosis, ZO-1/Cx43 
association was increased in the cytoplasm, suggesting that ZO-1 might play a role in the 
turnover of Cx43 during the endocytosis of gap junction plaques (Segretain et al., 2004). 
Overexpression of the connexin-interacting fragment of ZO-1 in ROS osteoblastic cells 
disrupted the Cx43/ZO-1 interaction reduced gap junction permeability. On the contrary, 
gap junction permeability and membrane staining for Cx43 were increased in ROS cells 
transfected with full-length ZO-1. These data indicate that Cx43 membrane localization 
and Cx43-mediated gap junction function in ROS osteoblastic cells is regulated by ZO-1 
(Laing et al., 2005). Knockdown of ZO-1 in lens epithelial cells results in accumulation 
of Cx43 aggregates inside the cells. These aggregates are not disassembled by PKC-
gamma activation and Cx43 phosphorylation. In these ZO-1 knockdown cells, the large 
Cx43 plaques are lost and consequently no functional dye transfer is observed. These data 
confrim a critical role for ZO-1 in the regulation of Cx43 function (Akoyev et al., 2007). 
Furthermore, ZO-1 also co-localizes with Cx43 in glial gap junctions of astrocytes and 
can be co-immunoprecipitated by Cx43 (Penes et al., 2005). The interaction between ZO-
1 and Cx43 can be regulated by c-Src. Active c-Src phosphorylates Tyr265 of Cx43 and 
inhibits the interaction between ZO-1 and Cx43 via binding to Cx43 through its SH2 
domain. The interaction between ZO-1 and mutant Cx43 lacking the c-Src 
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phosphorylation site, in contrast, is not affected by activated c-Src (Toyofuku et al., 
2001). 
In addition to Cx43, ZO-1 also interacts with other connexins. ZO-1 can be co-
immunoprecipitated with Cx45 due to its interaction with the C-terminal PDZ binding 
motif of Cx45. Endogenous ZO-1 co-localizes with wild type Cx45, but not a mutant in 
which the C-terminal PDZ-binding motif was inactivated, in tranfected MDCK cells 
(Kausalya et al., 2001). ZO-1 also co-localizes with alpha3 Cx46 and alpha8 Cx50 
throughout the lens. This interaction is via the second PDZ domain of ZO-1 and the C-
terminus of the two connexins (Nielsen et al., 2003). Co-localization of ZO-1 and Cx36 is 
widespread in the central nervous system. ZO-1 can pull down Cx36 via its first PDZ 
domain, while the four C-terminal amino acids of Cx36 are crucial for this interaction. 
Further studies demonstrated that ZO-1 and Cx36 co-localize at individual gap junction 
plaques (Li et al., 2004; Rash et al., 2004). ZO-1 co-localizes with Cx47 in 
oligodendrocytes and can pull it down through its second PDZ domain (Li et al., 2004). 
In glial gap junctions of astrocytes, also Cx30 co-localizes and co-precipitates with ZO-1. 
The second PDZ domain of ZO-1 is sufficient for its binding with Cx30 (Penes et al., 
2005). These data indicate that ZO-1 may play a crucial role in organizing gap junctions 
and recruiting signaling molecules that regulate intercellular communication. 
Other interaction partners 
ZO-1 also interacts with several other proteins, some of which are discussed below. 
ZO-1 binds actin via its C-terminal portion and can be immunoprecipitated with actin 
filaments in vitro. When the C-terminal portion of ZO-1 was transfected into mouse L 
fibroblasts, it localized to actin stress fibers (Itoh et al., 1997). Similarly, the 
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overexpressed C-terminal portion of ZO-1 locates along the lateral plasma membrane and 
other actin-rich structures in MDCK cells (Fanning et al., 1998). In addition, ZO-1 
interacts with the actin binding protein 4.1 (Mattagajasingh et al., 2000). These data 
suggest that ZO-1 might function as a linker between TM proteins and the actin 
cytoskeleton. 
ZO-1 furthermore interacts via its SH3 domain with a Y-box transcription factor, 
ZONAB (ZO-1-associated nucleic acid-binding protein) and negatively regulates ErbB-2 
promoter activity through ZONAB in a cell density-dependent manner. Stable 
overexpression of ZO-1 and ZONAB controls endogenous ErbB-2 expression. These data 
indicate that ZO-1 participates in the control of gene expression and might play a role in 
the regulation of epithelial cell differentiation (Balda et al., 2000). ZO-1 also interacts via 
its SH3 domain with the heat shock protein Apg-2. Apg-2 thus competes with ZONAB 
for binding to the SH3 domain of ZO-1, leading to the release of ZONAB and increased 
cell proliferation (Tsapara et al., 2006). 
The first PDZ domain of ZO-1 interacts with the TRL motif of TRPC4, which is a 
member of the mammalian transient receptor potential (TRP) protein family. TRPC4 
forms cation-permeable channels in the plasma membrane and membrane localization of 
TRPC4 depends on the C-terminal TRL motif that interacts with the ZO-1 PDZ domains 
(Song et al., 2005).  
The first PDZ domain of ZO-1 furthermore interacts with the cortical membrane 
scaffolding protein alpha-actinin-4 in both cultured cells and tissues, including brain and 
heart (Chen  et al., 2006). 
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1.3.1.5 ZO-1 functions, regulation and associated diseases 
ZO-1 functions 
ZO-1 is thought to be involved in TJ formation. At the initiation of cell-cell contact 
formation, ZO-1 localizes at the primordial cell-cell contact sites together with E-
cadherin to form spot-like junctions at the tips of cellular processes. As cellular 
polarization continues, occludin is recruited to the ZO-1-positive spot-like junctions and 
gradually forms belt-like TJs, while E-cadherin leaves the ZO-1-positive spot-like 
junctions to form belt-like adherens junctions (Ando-Akatsuka et al., 1999). However, 
knockout of the ZO-1 gene in Eph4 cells does not affect the formation of TJs and the 
establishment of cell polarity. In ZO-1 deficient Eph4 cells, occludin and claudins are 
normally recruited to the TJ region, while ZO-2 is up regulated and cingulin is down 
regulated. Ca2+ switch experiments indicate that ZO-1 deficiency does not affect adherens 
junction initiation, but delays the subsequent TJ formation (Umeda et al., 2004). However, 
if ZO-2 is silenced in ZO-1 deficient Eph4 cells, TJs are completely disrupted. 
Exogenous expression of either ZO-1 or ZO-2 can rescue the formation of TJs, 
suggesting that both ZO-1 and ZO-2 can independently determine the formation of TJs 
(Umeda et al., 2006). In ZO-1 knockout / ZO-2 knockdown cells, adherens junction 
formation is delayed, suggesting that ZO proteins are not only involved in TJ formation, 
but also play a role for AJ assembly. Mutational analysis indicated that ZO-1 might be 
directly involved in the formation of TJs and adherens junctions, but that its role in these 
two processes differs (Ikenouchi et al., 2007). 
ZO-1 is expressed in the blood-testis barrier. In carcinoma in situ (CIS) of 
seminiferous tubules, ZO-1 and ZO-2 mislocalize from the blood-testis barrier region of 
adjacent Sertoli cells to the Sertoli cell cytoplasm. Lanthanum tracer permeability studies 
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demonstrated that the integrity of the blood-testis barrier is disrupted; suggesting that ZO-
1 might play a crucial role in the blood-testis barrier (Fink et al., 2006).  
ZO-1 also participates in the regulation of gene expression. It interacts with the Y-
box transcription factor ZONAB to regulate the ErbB-2 promoter in a cell density-
dependent manner. Stable overexpression of ZO-1 and ZONAB controls the expression 
of endogenous ErbB-2 (Balda et al., 2000). ZO-1 may also play a role in regulating cell 
differentiation. Stable expression of the N-terminus of ZO-1 in corneal epithelial cells 
leads to a dramatic change in cell shape and gene expression. The cobblestone 
morphology of epithelial cells is lost in the transfected cells which show an elongated 
fibroblast-like appearence. Concomitantly, occludin is down regulated and the 
localization of endogenous ZO-1 and ZO-2 is disrupted (Ryeom et al., 2000). A similar 
EMT and an activation of Wnt signaling is observed in MDCK cells overexpressing the 
N-terminus of ZO-1 (Reichert et al., 2000) or in breast cancer cell lines where, due to the 
lack of occludin, ZO-1 is present in the cytosol (Polette et al., 2005).  
Regulation of ZO-1 
The localization of ZO-1 can be regulated by its phosphorylation of tyrosine. ZO-1 is 
phosphorylated during the rearrangement of TJs in glomeruli when there are rapid 
changes in epithelial cell shape, suggesting that ZO-1 phosphorylation might be required 
for the re-organization of TJs (Kurihara et al., 1995). The phosphorylation status of ZO-1 
can be regulated by epidermal growth factor (EGF) in A431 human epidermal carcinoma 
cells. Addition of EGF to A431 cells results in phosphorylation of ZO-1 on tyrosine 
residues. Concomitantly, ZO-1 is redistributed from the lateral membranes to apical sites 
of cell-cell contact, indicating that the transient tyrosine phosphorylation of ZO-1 might 
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be involved in the rearrangement of the intercellular junctions. EGF also causes actin re-
organization, which is required for EGF-induced rearrangement of ZO-1 (Van Itallie et 
al., 1995). ZO-1 localization furthermore depends on rab3B. Stable expression of rab3B 
in PC12 neuroendocrine cells leads to redistribution of ZO-1, while a mutant rab3B 
(N135I) has no effect (Sunshine et al., 2000). ZO-1 expression levels are directly affected 
by PKC in T84 cell line. Activation or inhibition of PKC induces or decreases ZO-1 
transcription, respectively (Weiler et al., 2005). 
ZO-1 and associated diseases 
ZO-1 in celiac disease and kidney diseases 
ZO-1 is downregulated in duodenal mucosa of active celiac disease patients 
(Montalto et al., 2002). ZO-1 is also lost in dextran sulfate sodium (DSS) induced colitis. 
Further analysis showed that loss of ZO-1 and increased permeability start before the 
development of significant intestinal inflammation, suggesting that DDS induced colitis 
is a consequence of the alterations in the TJ complex (Poritz et al., 2007). In addition to 
celiac disease, ZO-1 is also involved in kidney diseases. ZO-1 can recruit claudin 16 to 
the TJs in kidney epithelium cells. In human patients carrying a muation in claudin 16 
that inactivates the PDZ binding motif, claudin 16 no longer localizes to the TJs but 
accumulates in lysosomes. This mislocalization of claudin 16 leads to familial 
hypomagnesemia with hypercalciuria and nephrocalcinosis (Müller et al., 2003). ZO-1 is 
also down regulated or mislocalized in the kidney of diabetic animals, where it is no 
longer found on the podocyte membrane and instead shows a diffuse cytoplasmic 
distribution, suggesting that ZO-1 might be involved in pathogenesis of proteinuria in 
diabetes (Rincon-Choles et al., 2006). Consistent with these observations, high glucose 
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medium reduces ZO-1 expression levels and disturbs the membrane localization of ZO-1 
in glomerular epithelial cells in vitro.  
ZO-1 and tumorigenesis 
The role of ZO-1 in tumorigenesis remains ambiguous. ZO-1 expression is 
significantly downregulated in breast cancers and this correlates with tumor 
differentiation. The lower the ZO-1 expression levels, the less differentiated the tumor. 
Concomitantly, reduced ZO-1 expression strongly correlates with lower E-cadherin 
expression levels (Hoover et al., 1998). In squamous cell carcinoma (SCC), ZO-1 
expression levels and patterns are also changed. While overall reduced, ZO-1 is strongly 
expressed in the keratinized tumor cells. In contrast, in normal epidermis, it is mainly 
expressed at the cell-cell borders of the granular layer (Morita et al., 2004). Furthermore, 
ZO-1 expression has been implicated in metastasis formation. ZO-1 is downregulated in 
primary colorectal cancer (CRC) with liver metastasis but re-expressed in liver 
metastasized cancers. Further studies indicated that ZO-1 interacts with epidermal growth 
factor receptor (EGFR) in CRC with liver metastasis and the bound ZO-1 protein is 
highly phosphorylated on tyrosine residues, while ZO-1 expressed in liver metastasized 
cancer is dephosphorylated. These data suggest a critical role for ZO-1 in CRC metastasis 
(Kaihara et al., 2003). In pancreatic adenocarcinoma, however, ZO-1 is upregulated and 
displays a variety of staining patterns in metastatic pancreatic cancer cells within lymph 
nodes. Some cells show apical and apical-lateral staining while others display a diffused 
membranous staining. Overexpression of ZO-1 in pancreatic adenocarcinoma might 
facilitate the metastasis of pancreatic cancer cells (Kleeff et al., 2001). Disruption of ZO-
1 localization to the sites of cell-cell contact induces ERK2 and p-ERK1/2 expression and 
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results in dissociation of cell clones from pancreatic tumors, suggesting that ZO-1 might 
regulate cell adhesion of pancreatic cancer cells via activation of ERK2 (Tan et al., 2005). 
Furthermore, ZO-1 is expressed in most synovial sarcoma, indicating a partial epithelial 
differentiation of the sarcoma (Billings et al., 2004). 
1.3.2 ZO-2 
1.3.2.1 Molecular structure of ZO-2 
The TJ protein ZO-2 has a molecular weight of 160 kDa and, as a member of the 
MAGUK protein family, contains three PDZ domains, one SH3 domain, and one GUK 
domain. Like ZO-1, ZO-2 has a proline-rich C-terminal region that is not conserved in 
other MAGUK family members (Figure 4). ZO-2 shares high amino acid identity with 
ZO-1 except in the C-terminus, which might contribute to the different functions of these 
two proteins (Beatch et al., 1996). ZO-2 contains several nuclear localization signals 
(NLS) in the N-terminal region (González-Mariscal et al., 2006). It also has four putative 
nuclear export signals (NES), two of which are found in the second PDZ domain, the 
other two in the GUK region (Jaramillo et al., 2004). In confluent MDCK cell cultures 
ZO-2 localizes to the plasma membrane, but it is found in the nucleus in sparse cultures 
(Islas et al., 2002). The change of its subcellular localization depending on cell 
confluency suggests a role for ZO-2 in regulating gene expression in response the cell-
cell adhesion status. 
1.3.2.2 Interaction partners of ZO-2 
ZO-2 interacts with a large and growing number of interaction partners. 
Immunoprecipitation experiments show that ZO-2 binds to ZO-1 via the second PDZ 
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domains. When the N-terminal portion of ZO-2 was expressed in cultured cells, it co-
localized with endogenous ZO-1/ZO-2.  ZO-2 also binds through its GUK domain to 
occludin to form a complex with ZO-1/occludin that is important for the establishment of 
TJ domains (Itoh et al., 1999). Through the first PDZ domain, ZO-2 binds to the C-
terminal YV sequence of claudin-1 to -8 (Itoh et al., 1999) but not to the TRV motif of 
Cldn16 (Müller et al., 2003). Like ZO-1, ZO-2 can independently determine the site of 
polymerization of claudins (Umeda et al., 2006). ZO-2 binds to the N-terminal fragment 
of cingulin, which links the sub-membranous plaque domain of TJs to the actin 
cytoskeleton (Cordenonsi et al., 1999). Similar to ZO-1, ZO-2 is present in adherens 
junctions in non-epithelial cells such as fibroblasts and cardiac muscle cells. In adherens 
junctions, ZO-2 interacts withα -catenin to form a complex with ZO-1/α -catenin 
involved in the establishment of adherens junction domains (Itoh et al., 1999). ZO-2 
directly binds to F-actin and the C-terminal portion of ZO-2 expressed in cultured cells 
co-localizes with actin filaments (Wittchen et al., 1999). ZO-2 can also be co-precipitated 
by the actin binding protein 4.1 and the interaction occurs via the amino acids encoded by 
exons 19-21 of 4.1R and residues 1054-1118 of ZO-2. By immunofluorescence 
microscopy, ZO-2 co-localizes with the actin binding protein 4.1R at TJs in MDCK cells 
(Mattagajasingh et al., 2000). ZO-2 also interacts with ARVCF, an armadillo-repeat 
protein of the p120Ctn family found in AJs and may play a role in the recruitment of 
ARVCF to the plasma membrane (Kausalya et al., 2004). Interestingly, ZO-2 also binds 
via its C-terminal motif to two PDZ domains of hScribble (Métais et al., 2005), a 
component of the Scrib polarity complex, highly conserved in evolution from worms to 
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mammals (Assémat et al., 2007). A functional significance of this interaction, however, 
has not been established.  
In addition to integral membrane and cytosolic components of TJs and AJs, ZO-2 
also associates with nuclear proteins. In sparse cell cultures, ZO-2 concentrates in the 
nucleus and co-localizes with splicing factor SC35 (Islas et al., 2002). ZO-2 has also been 
shown to directly interact with the DNA-binding protein scaffold attachment factor-B 
(SAF-B), an interaction mediated by the first PDZ domain of ZO-2 and the C-terminus of 
SAF-B (Traweger et al., 2003). Interestingly, ZO-2 directly associates with several 
transcription factors, in particular Jun, Fos and C/EBP, in epithelial cells (Betanzos et al., 
2004). These findings suggests that ZO-2 not only functions at the level of TJs but that it 
may be involved regulating gene expression linked to cell proliferation and/or 
differentiation. 
1.3.2.3 ZO-2 and associated diseases 
There is evidence to support a role for ZO-2 as a tumor suppressor gene. In humans, 
two ZO-2 isoforms, namely ZO-2A and ZO-2C, the latter lacking the first 23 amino acids 
present in ZO-2A, are differentially expressed in normal and neoplastic cells. ZO-2C is 
expressed in both normal and neoplastic tissues, while ZO-2A is absent from pancreatic 
adenocarcinomas (Chlenski et al., 1999a). The loss of ZO-2A expression in neoplastic 
cells is due to the inactivation of the downstream promoter P(A) (Chlenski et al., 1999b). 
Methylation analysis also showed that ZO-2 is aberrantly methylated in 64% of 42 
pancreatic cancers analyzed as compared to 10 normal pancreatic ductal epithelial 
samples (Sato et al., 2003). In addition to pancreatic adenocarcinoma, ZO-2 is also lost or 
significantly decreased in a majority of breast adenocarcinomas. (Chlenski et al., 2000). 
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ZO-2 is a cellular target of the tumorigenic Ad9 E4-ORF1 protein, which interacts with 
the first PDZ domain of ZO-2 via its C-terminal PDZ-binding motif. Over-expression of 
ZO-2 can repress the neoplastic growth of cells activated by Ad9 E4-ORF1 protein 
(Glaunsinger et al., 2001). 
ZO-2 has also been implicated in human diseases other than cancer. Point mutations 
in first PDZ domain of ZO-2 have been linked to familial hypercholanemia (FHC), a 
condition characterized by elevated serum bile acid concentrations, itching, and fat mal-
absorption (Carlton et al., 2003). ZO-2 is involved in maintaining the integrity of the 
blood-testis barrier. In CIS of seminiferous tubules, ZO-2, together with ZO-1, is 
mislocalized from the blood-testis barrier region to the cytosol of Sertoli cells and this 
change in localization correlates with a functional disruption of the TJ barrier (Fink et al., 
2006).  
1.3.3 ZO-3 
1.3.3.1 Molecular structure of ZO-3 
ZO-3 is a 130-kDa protein with, similar to ZO-1 and ZO-2, three PDZ domains, one 
SH3 domain, one GUK domain and a C-terminal acidic domain and a basic region 
between the first and second PDZ domains. The main differences compared to ZO-1 and 
ZO-2 are the location of the proline rich region between the second and third PDZ 
domain of ZO-3 (Figure 4) and to the lack of alternative splicing (Haskins et al., 1998). 
ZO-3 has two putative bipartite nuclear localization signals (NLS) (González-Mariscal et 
al., 1999) and one nuclear export signals (NES) (Islas et al., 2002), however, there is no 
evidence for a nuclear localization of ZO-3 so far. Unlike ZO-1 and ZO-2, ZO-3 is only 
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expressed in different epithelia and not in endothelia. ZO-3 is also not found at sites of E-
cadherin-based cell-cell adhesion (Inoko et al., 2003). 
1.3.3.2 Interaction partners of ZO-3 
ZO-3 can be co-precipitated with ZO-1 and based on immunofluorescence 
experiments, it co-localizes with ZO-1 at TJs. In vitro binding analysis demonstrated that 
ZO-3 directly interacts with ZO-1 and the cytoplasmic domain of occludin, but not with 
ZO-2 (Haskins et al., 1998). Further studies indicated that ZO-1, ZO-2, and ZO-3 do not 
exist in situ as a trimeric complex but as independent ZO-1/ZO-2 and ZO-1/ZO-3 
complexes (Wittchen et al., 1999). Like ZO-2, ZO-3 binds to the C-terminal YV 
sequence of claudin-1 to -8 through its first PDZ domain in vitro (Itoh et al., 1999) and 
not to the TRV motif in Cldn16 (Müller et al., 2003). Pull-down analysis indicated that 
ZO-3 interacts with both the N-terminal and C-terminal parts of cingulin, while ZO-1 and 
ZO-2 only interact with the N-terminal part of cingulin (Cordenonsi et al., 1999). ZO-3 
(and ZO-1 but not ZO-2) binds via PDZ domains to Cx45 (Kausalya et al., 2001). These 
observations indicate that despite their high similarity, the PDZ domains of ZO proteins 
interact with specific ligands. This notion has been confirmed by analyzing the specificity 
of individual PDZ domains using small peptides displayed on phage (Sidhu et al., 2003). 
ZO-3 interacts directly with F-actin in vitro and immunofluorescence analysis shows that 
ZO-3 co-localizes with F-actin aggregates at cell borders in cytochalasin D-treated 
MDCK cells (Wittchen et al., 1999). While ZO-2 associates with the Scrib polarity 
complex, ZO-3 interacts via its C-terminus with one of the PDZ domains of PATJ (Roh 
et al., 2002). PATJ is a component of Crumbs, a polarity complex conserved during 
evolution from worms to mammals (Assémat et al., 2007). ZO-3 also interacts with p120 
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catenin and AF-6 (Wittchen et al., 2003), suggesting a possible role of ZO-3 in signal 
transduction. 
1.3.3.3 Functions of ZO-3 
Expression of the N-terminal region of ZO-3 (NZO-3) in MDCK cells delays the 
assembly of both TJs and AJs, consistent with a role in junction formation. 
Immunofluorescence analysis indicated that ZO-1, ZO-2, endogenous ZO-3, and occludin 
are mislocalized during initial steps of TJ assembly and that recruitment of E-cadherin 
and β-catenin to the cell membrane is delayed. A larger fraction of β-catenin is Triton X-
100-soluble during the early stages of TJ assembly in the cells expressing NZO-3 protein 
(Wittchen et al., 2000), suggesting that NZO-3 might exert a dominant negative role on 
junction assembly via β-catenin. Further studies demonstrated that NZO-3 expression in 
MDCK cells decreases the number of stress fibers and focal adhesions and increases cell 
migration rate in a wound-healing assays. Expression of NZO-3 alters the interactions 
between endogenous ZO-3 and p120Ctn, which may affect RhoA activity and RhoA-
related signaling events (Wittchen et al., 2003). Since PATJ lacking the PDZ domain 
required for interaction with ZO-3 is not present in cell-cell contacts, ZO-3 could 
function in establishing cell polarity by recruiting PATJ and its associated proteins to TJs 
(Roh et al., 2002). However, recent analysis in Zebrafish indicates that depletion of ZO-3 
does not affect PATJ localization (Kiener et al., in press). Furthermore, in the course of 
my studies, a ZO-3 KO mouse was published which was viable and fertile and did not 
show any phenotype. F9 teratocarcinoma cell lines deficient in ZO-3 can be differentiated 
to form normal visceral endoderm epithelium-like cells, which have a normal TJ structure. 
These data suggest that ZO-3 is dispensable for both TJ formation and viability in the 
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mouse (Adachi et al., 2006). Interestingly, however, depletion on ZO-3 in zebrafish leads 
to a permeability defect of the enveloping cell layer of embryos (Kiener et al., in press). 
1.4 Rationale and aim of research 
Since the discovery of ZO-1 two decades ago, the ZO proteins have been widely 
studied. Their structures have been unveiled, their expression patterns determined, many 
interaction partners discovered and putative roles in TJ structure and function explored. 
However, despite being the best studied TJ proteins, their precise physiological role 
remains unclear and many questions are still unanswered. For example, ZO proteins are 
expressed in the early stage of embryo development, but their function during the 
different stages of development is not clear. Furthermore, ZO proteins are widely 
expressed in the tissues of adult animals, but their precise physiological functions remain 
to be determined. In particular, it is not clear if the three ZO-proteins exert redundant or 
unique functions and, if unique, how these functions differ. ZO proteins not only localize 
to TJs, but also to adherens and gap junction and their function in those structures are 
poorly characterized. Similarly, their roles in non-epithelial or endothelial cells, such as 
Schwann cells or cardiac myocytes, remain largely unknown. ZO proteins can shuttle 
between plasma membrane and the nucleus, but their role in the nucleus has only recently 
been started to be unraveled. Similarly, their possible importance in human diseases, in 
particular as possible tumor suppressors, remains ambiguous.  
The aim of this thesis was to study the function of ZO proteins in a physiological 
context using gene knockout strategies. In order to explore the physiological role of 
different ZO proteins during development and in various tissues, ZO knockout mice were 
generated by homozygous recombinanation. Due to the possible compensation between 
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individual ZO proteins, double knockout mice were also generated by crossing different 
single knockout strains. As a complementary approach, ZO knockout ES cells were 
produced by multiple gene targeting. These ZO deficient ES cells can not only be 
differentiated into embryloid bodies (EBs) to study the role of ZO proteins during early 
stages in development, but they can also be differentiated into different cell types (i.e. 
neurons or cardiomyocytes) to explore a possible role of ZO proteins in ES cell 
differentiation. Furthermore, ES cells can be used to generate chimeric mice to 
circumvent possible embryonic lethality. Finally, ES cells lacking ZOs can form teratoma 















Chapter 2 Materials and Methods 
2.1 Generation of ZO-1-/+ ES cells 
Genomic fragments containing the ZO-1 locus were isolated from a mouse 129Sv 
genomic library (Stratagene) and subcloned into pBluescript II KS+ (Stratagene). A 
targeting vector with a LacZ neo cassette flanked by short and long arms of 3.6 kb and 
6.7 kb for ZO-1 was designed to replace the exon containing the first transcriptional 
ATG. The targeting vector was linearized and electroporated into W4 embryonic stem 
cells (Taconic Transgenics), which were then selected with 250 µg/ml G418. After 7-9 
days selection, the remaining colonies were picked and screened by long-range PCR. 
2.2 Generation of ZO-2-/+ ES cells 
Genomic fragments containing the ZO-2 locus were isolated from a mouse 129Sv 
genomic library (Stratagene) and subcloned into pBluescript II KS+ (Stratagene). A 
targeting vector with a LacZ neo cassette flanked by short and long arms of 1.8 kb and 
5.9 kb for ZO-2 was designed to replace the exon containing the first transcriptional ATG. 
The targeting vector was linearized and electroporated into W4 embryonic stem cells, 
which was then selected with 250µg/ml G418. After 7-9 days selection, the remaining 
colonies were picked, screened by long-range PCR and confirmed by Southern blot later. 
2.3 Generation of ZO-3-/+ ES cells 
Genomic fragments containing the ZO-3 locus was isolated from a mouse 129Sv 
genomic library (Stratagene) and subcloned into pBluescript II KS+ (Stratagene). A 
targeting vector with a LacZ neo cassette flanked by short and long arms of 2.2 kb and 
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4.8 kb for ZO-3 was designed to replace the exon containing the first transcriptional ATG. 
The targeting vector was linearized and electroporated into W4 embryonic stem cells, 
which were then selected with 250µg/ml G418. After 7-9 days selection, the remaining 
colonies were picked, screened by long-range PCR and confirmed by Southern blot later. 
2.4 Generation of ZO-1-/- ES cells 
ZO-1-/+ ES cells were seeded in a 6-well plate. After two days, these cells were 
trypsinized and replated onto a 10 cm dish and selected with 20 mg/ml G418 
(CALBIOCHEM). After 7-9 days of selection, drug-resistant colonies were picked. Half 
of the cells from each clone were screened with PCR and the other half were expanded on 
feeder cells. The targeting ES cell clones were amplified and confirmed by Western blot. 
Six independent ZO-1-/- ES cell clones were obtained from the screening. 
2.5 Generation of ZO-2-/- ES cells 
Independent ZO-2-/+ ES cells were seeded in a 6-well plate. After two days, these 
cells were trypsinized and replated onto a 10 cm dish and selected with 20 mg/ml G418 
(Calbiochem). After 7-9 days of selection, drug-resistant colonies were picked. Half of 
the cells from each clone were screened with PCR and the other half were expanded on 
feeder cells. The targeting ES cell clones were amplified and confirmed by Western blot. 
Eight independent ZO-2-/- ES cell clones were obtained from two independent ZO-2-/+ 
mother ES cell lines. 
2.6 Isolation of ZO-3 -/- ES cells 
Six to eight-week-old 129SvJ ZO-3-/- female mice were mated with ZO-3-/- 129Sv 
males. On E3.5 (Plug=0.5 day), females were sacrificed to collect uteri, and balstocysts 
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were flushed out from the uteri with M2 media (Sigma). The blastocysts were then 
transferred into the wells of 96-well U-shape plates and cultured with ES cell medium. 
After four days, individual cell colonies were picked, trypsinized and mechanically 
dissociated. Inner cell mass cells were picked and transferred to 48-well plates with 
feeder cells. Around 8 days, colonies with ES cell-like morphology were observed. They 
were trypsinized, dissociated, and replated onto another 48-well plate with fresh feeder 
cells. Around 5 days later, ES cell colonies could be clearly observed. These cells were 
amplified and used for analysis. Two independent ZO-3-/- ES cell clones were isolated 
from the inner cell mass. 
2.7 Generation of ZO-1-/- ZO-2-/-ES cells 
The Neo gene in ZO-1 mutant allele was flanked with two loxp sites. ZO-1-/- ES 
cells were transfected with cre-pac plasmid (Taniguchi et al. 1998), which expresses the 
cre protein to specifically delete the neo sequence from the chromosome. After 
transfection, cells were cultured in ES cell culture media for 16 to 24 hours and then 
selected with puromycin for 48 hours. The surviving colonies were picked, trypsinized 
and dissociated. Half of the cells from each clone were cultured with normal ES cell 
culture media and the other half was selected with 500µg/ml G418. The neo sequence 
was deleted by cre in the clones that did not survive the G418 selection. The targeted 
clones were amplified and transfected with the ZO-2 targeting vector. ZO-2 knockout in 
the ZO-1 -/- ES cell line was achieved in analogy to the approach described for the 
generation of ZO-2-/- ES cells. ZO-1 and ZO-2 double knockout was confirmed by 
Western blot analysis. Seven independent ZO-1-/-ZO-2-/- ES cell clones were obtained 
from the screening. 
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2.8 Generation of ZO-2-/-ZO-3-/- ES cells 
The Neo gene in ZO-3 mutant allele was flanked with two loxp sites. ZO-3-/- ES 
cells were transfected with cre-pac plasmid (Taniguchi et al. 1998), which expresses the 
cre protein to specifically delete the neo sequence from the chromosome. After 
transfection, cells were cultured in ES cell culture media for 16 to 24 hours and then 
selected with puromycin for 48 hours. The surviving colonies were picked, trypsinized 
and dissociated. Half of the cells from each clone were cultured with normal ES cell 
culture media and the other half was selected with 500µg G418. The neo sequence was 
deleted in the clones that did not survive the G418 selection. The clones were amplified 
and transfected with the ZO-2 targeting vector. ZO-2 and ZO-3 double knockout was 
confirmed by Western blot analysis. Five independent ZO-2-/-ZO-3-/- ES cell clones 
were obtained from the screening. 
2.9 Generation of ZO-1 chimeric mice and embryos 
ZO-1-/+ and ZO-1-/- ES clones were injected into blastocysts derived from C57BL/6 
mice to generate chimeric mice and embryos. 
2.10 Generation of ZO-2 chimeric and knockout mice 
ZO-2-/+ and ZO-2-/- ES clones were injected into blastocysts derived from C57BL/6 
mice to generate chimeras. ZO-2 -/+; +/+ chimeras with germ line transmission were 
used to generate ZO-2 knockout mice.  
2.11 Generation of ZO-3 knockout mice 
ZO-3-/+ ES clones were injected into blastocysts derived from C57BL/6 mice to 
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generate chimeras. The chimeras with germ line transmission were used to generate ZO-3 
knockout mice. 
2.12 Southern blot analysis 
Genomic DNA was extracted from G418-resistant ES cell clones and completely 
digested with Scal I.  For ZO-2, a 566-bp fragment, corresponding to the 5’ end of the 
right arm of the target vector, was labeled with [32P] dCTP by random priming (Roche) 
and used as a probe. For ZO-3, a 679-bp fragment, corresponding to the 3’ end of the left 
arm of the target vector, and a 668-bp fragment, corresponding to the neo sequence, were 
labeled with [32P] dCTP and used as probes.  
2.13 PCR genotyping  
For genotyping, genomic DNA isolated from tail clippings or embryo tissue and 
suitable primers were used in a PCR reaction. Primer 1 (5’-atg gag gag gtg ata tgg gag 
cag-3’) and primer 2 (5’-tgt gtc att ggt gtg tgg aag gag-3’) were used amplify a fragment 
of 367 bp for the WT allele, whereas primer 3 (5’-gag ctg tgt gga agc ata cct agt-3’) and 
primer 4 (5’-atg gga tag gtt acg ttg gtg tag-3’) yielded a 580 bp product for the mutant 
allele of ZO-2. For ZO-3, primer 5 (5’-gag gta tag tgg gta agc cag aca-3’) and primer 6 
(5’-aag gcg tta ctt ctc aga ccc ag-3’) amplified a 297 bp fragment for the WT allele, 
whereas primer 7(5’-gag gta tag tgg gta agc cag aca-3’) and primer 8 (5’-atg gga tag gtt 
acg ttg gtg tag-3’) resulted in a 679bp product for the mutant allele. 
2.14 Histological analysis 
E5.5-E8.5 embryos within deciduas and mouse organs were fixed in 4% 
paraformaldehyde overnight, embedded in paraffin, sectioned and stained with 
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hematoxylin and eosin. The slides were viewed with a Leica DM4000 B microscope and 
photos were taken with a DFC300 FX camera. For genotyping embryos, tissue was 
micro-dissected from paraffin sections and digested in 20μl water containing 10μg 
proteinase K (Roche) at 56°C for 2 hours. Proteinase K was then inactivated at 80°C for 
10 minutes and 2μl of the digest used for PCR analysis. 
2.15 Immunostaining 
Embryos dissected from deciduas, EBs, and mouse organs were embeded in OCT 
and sectioned at a thickness of 5μm. Immunostaing was carried out with rabbit 
polyclonal antibodies against ZO-1, ZO-2, ZO-3, occludin, cingulin, claudin 1-8 (Zymed), 
Brachyury (Abcam and Saint Cruz), and rat polyclonal antibodies against E-cadherin 
(Zymed) and prominin (eBioscience) 
2.16 Isolation and culture of blastocysts in vitro 
8 to 10 weeks old males and females were crossed and the blastocysts collected at 
3.5 dpc by flushing the uterus of plugged females with M2 medium (Sigma). Flushed 
blastocysts were then cultured individually in Dulbecco’s modified Eagle’s medium 
(DMEM) supplemented with 20% fetal bovine serum (FBS) in 96-well plates at 37°C in 
5% CO2. 
2.17 Transmission electron microscopy  
E6.5-E7.5 embryos and EBs were fixed in 2.5% glutaraldehyde.  After rinsing with 
0.1 M PBS, the samples were postfixed in 1% osmium tetroxide for 1 hour, rinsed in 
phosphate buffer, dehydrated in ethanol and embedded in resin. Ultrathin sections were 
cut with a diamond knife, stained with uranyl acetate and lead citrate, and then viewed 
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with a transmission electron microscope (JEM-1010) 
2.18 Lanthanum Nitrate Tracer Study 
E7.5 embryos and Day 5 EBs were immediately fixed in 2.5% freshly made 
glutaraldehyde for 1-3 hours.  In some experiments, WT EBs were incubated with 10 mM 
EGTA for 30 min on ice before fixation in 2.5% glutaraldehyde. After rinsing with 0.1 M 
PBS, the samples were postfixed in 1% osmium tetroxide containing 1% lanthanum 
nitrate for 1 hour, rinsed in phosphate buffer, dehydrated in ethanol and embedded in 
resin. Ultrathin sections were cut with a diamond knife, stained with uranyl acetate and 
lead citrate, and then viewed with a transmission electron microscope (JEM-1010) 
2.19 Permeability analysis 
The barrier function of epithelial cells of cystic EBs was analyzed using a surface 
biotinylation technique (Chen et al., 1997) with modifications (Saitou et al., 1998). 
Briefly, WT and ZO protein deficient cystic EBs were incubated in freshly made 1 mg/ml 
NHS-LC-biotin (Pierce Chemical Co.) in PBS for 30 min on ice. In control experiments, 
WT cystic EBs were incubated with NHS-LC-biotin in the presence of 10 mM EDTA. 
After washing with PBS, the EBs were fixed, embedded in OCT, and sectioned at a 
thickness of 1μm. The sections were rinsed with PBS, blocked in 1% BSA-PBS for 1 
hour and then stained with phalloidin (1:200; Pierce Chemical Co.) or avidin (1:200; 






2.20 In situ cell death assay  
Tunnel (terminal deoxynucleotidyltransferase-mediated dUTP-biotin nick end 
labeling) assays were done on cryo-sections of mouse embryos from E6.5 to 8.5, EBs, 
and testis with the TMR red In Situ Cell Death Detection Kit (Roche) according to the 
manufacturer’s protocol.  
2.21 BrdU labeling  
For embryos, 2 hour before sacrificing the mice, 100 µg of bromodeoxyuridine 
(BrdU; Sigma) per gram of body weight was injected peritoneally into the pregnant 
females. Deciduae were removed and processed as described above. The sections were 
stained with the In Situ Cell Proliferation Kit, FLUOS (Roche) according to the 
manufacturer’s protocol. 
EBs were cultured in the medium containing 10mM BrdU at 37ºC for 1 hour and then 
embedded in OCT, sectioned and stained with the In Situ Cell Proliferation Kit, FLUOS 
(Roche). 
2.22 EB differentiation 
ES cell were seeded on gelatin-coated plates without feeder cells. After 2 days 
culture, cells were trypsinized and dissociated. To allow for differentiation, ES cells were 
cultured with ES cell culture media without leukemia inhibitory factor (ESGRO; 
Chemicon) in bacterial dishes. Media was changed every two days. Around Day 10, 
cystic EBs were formed. 
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2.23 Preparation of lysates 
ES cells or EBs were washed twice with PBS and lysed for 45 minutes with RIPA 
buffer (1% deoxycholate, 1% Triton, 0.5% SDS, 50mM Na2HPO4, 150mM NaCl, 2mM 
EDTA) on ice. For mouse tissue lysates, the organs were homogenized, sonicated, and 
then lysed for 45 minutes with RIPA buffer on ice. Lysates were centrifuged at 13,000 g 



































Chapter 3 Generation and phenotypic analysis 
of ZO-1 chimeric mice and embryos 
3.1 Generation of ZO-1-/+ and ZO-1-/- ES cells 
      Genomic fragments containing the ZO-1 locus were isolated from a mouse 129Sv 
genomic library and subcloned into pBluescript II KS+. A targeting vector with a LacZ 
neo cassette flanked by short and long arms of 3.6 kb and 6.7 kb ZO-1 genomic DNA 
framgemts was designed to replace the exon containing the first ATG translational 
initiation codon (Figure 5A). This insertion leads to a null mutation of the corresponding 
gene and in principle allows the expression of the β-gal marker under the control of the 
endogenous transcriptional regulatory elements of the ZO-1 gene. 
      The targeting vector was linearized with Sal I restriction enzyme and electroporated 
into W4 ES cells, which were selected with 250 µg/ml G418. After 7-9 days under 
selection, the surviving colonies were picked and screened by long-range PCR (Figure 
5B). Of the 96 G418-resistant clones examined, 3 had undergone a single homologous 
recombination. 
      To generate ZO-1-/- ES cells, independent ZO-1-/+ ES cells were selected in 20 
mg/ml G418. After 7-9 days of selection, drug-resistant clones were picked and screened 
by PCR (Figure 5C). The targeting clones were amplified and the loss of ZO-1 protein 
was confirmed by Western blot (Figure 6A). Six independent ZO-1-/- clones were 
generated. Since these 6 clones showed the same phenotype in terms of TJ structure, cell 
proliferation and cell death, the data obtained from one clone, clone 23, was taken as 
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representative of the 6 clones. ZO-1-/- ES cells did not show any morphological 
differences compared to ZO-1+/+ ES cells (Figure 6B).  
 
Figure 5 Targeting of ZO-1 locus and PCR screening. (A) Schematic representation of 
the genomic locus of ZO-1 shows exon 1 with the initiation ATG. The targeting vectors 
were designed to disrupt exon 1 by the in-frame insertion of a lacZ gene and a loxP 
flanked neomycin cassette immediately downstream of the ATG codon. Red and green 
arrows denote the regions from where primers were derived to screen for heterozygous 
and knockout ES cells, respectively. (B, C) Homologous recombination in ES cells. PCR 
screening was done on selected ES cell clones with the indicated primers (see panel A) to 
identify homologous recombinants. A 4021 bp fragment is indicative of the presence of 
the recombined mutant ZO-1 allele (panel B), while the 255 bp fragment denotes the WT 






Figure 6 Characterization of ZO-1-/- ES cell lines. (A) Western blot analysis was done 
on lysates from 6 ES cell lines to access the expression of ZO-1, ZO-2, and ZO-3. No ZO-
1 expression was detected in ZO-1-/- ES cell lines and expression was downregulated in 
ZO-1-/+ ES cell lines, while the expression of ZO-2 and ZO-3 was unaffected. (B) 

















3.2 ZO-1 chimeric mice 
      ZO-1-/+ ES cells were injected into blastocysts in an attempt to generate ZO-1-/+;+/+ 
chimeric mice and possibly obtain germline transmission. However, injection of ZO-1 
heterozygous ES cells did not yield chimeric mice with a high percentage Agouti coat 
color and no germ line transmission was obtained. 
      Chimeric embryos generated by injecting ZO-1-/- cells into blastocysts died at early 
embryonic stages around E9.5. As shown in Figure 7, chimeric embryos carrying ZO-1-/- 
cells were smaller in size than the ZO-1+/+ embryos. Variablity in the size of the ZO-1-/-
;+/+ chimeric embryos could be due to differences in the number of ZO-1-/- cells they 
carried. The reason for the embryonic lethality will be elucidated in a future study. 
 
Figure 7 ZO-1-/-;+/+ chimeric mice are embryonic lethal. ZO-1-/-;+/+ embryos die 







While we have not been able to generate ZO-1-/- mice so far, chimeric embryos 
derived from ZO-1-/- ES cells died around E9.5. Thus, it is likely that ZO-1-/- mice will 
also die at the embryo stage, probably at or before E9.5. Our analysis of ZO-1-/- EBs, 
however, suggests that ZO-1 plays a role in different aspects of embryo development (see 
Chapter 8). We found that ZO-1 deficiency affects the structure of TJs in the epithelia of 
the EBs. This is in contrast to reports that inactivation by homologous recombination or 
silencing of ZO-1 in Eph4 cells or MDCK cells, respectively, does not alter the structure of 
TJs (Umeda et al., 2004; Mcne et al., 2006). Since EBs recapitulate the early stages of 
embryo development (Doetschman et al., 1985), the structure of TJs in ZO-1-/- embryos is 
probably also affected. In addition, we found that ZO-1 deficiency led to the 
overexpression of T-gene, which is crucial for mesoderm development (Rashbass et al., 
1991). Thus, ZO-1 deficiency may affect mesoderm development via the deregulation of T-
gene expression. Furthermore, cell proliferation in EBs lacking ZO-1 was enhanced. ZO-1 
has been linked to the regulation of proliferation and differentiation through its association 
with ZONAB (Balda et al., 2003) and its link to the Wnt pathway (Reichert et al., 2000; 
Polette et al., 2006) and it will be of interest to determine in future studies whether these 





Chapter 4 Generation and phenotypic 
analysis of ZO-2 null mice 
4.1 Generation of ZO-2-/+ ES cells 
      Genomic fragments containing the ZO-2 locus were isolated from a mouse 129Sv 
genomic library and subcloned into pBluescript II KS+ vector. A targeting vector 
designed to replace the exon containing the first transcriptional ATG was constructed 
using a LacZ neo cassette flanked by short and long arms of 1.8 kb and 5.9 kb for ZO-2 
(Figure 8A). This insertion leads to a null mutation of the corresponding gene and in 
principle allows the expression of the β-gal marker under the control of the endogenous 
transcriptional regulatory elements of ZO-2. 
      The targeting vector was linearized with Sal I restriction enzyme and electroporated 
into the W4 ES cells. After 36 to 48 hours in culture, the transfected ES cell were 
subjected to selection of G418. The growing clones were screened for homologous 
recombination at the ZO-2 locus by means of long-range PCR using the primers indicated 
in Figure 8A. A band of ~1.9 kb was amplified for the targeted ES cell clones and two 
out of 96 clones analyzed were positive. PCR results were confirmed by Southern blot 
hybridization using the probes shown in Figure 8A. For each of the 2 targeted clones 
(#105 and #133), a 6.7 kb wild-type and an 11.5 kb mutant band was detected, while wild 
type clones (lane3) only showed the 6.7 kb band (Figure 8B). 
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Figure 8 Targeting of the ZO-2 gene (A) Schematic representations of the genomic locus 
of the ZO-2 gene shows exon 2 with the initiation ATG. The targeting vector was 
designed to disrupt exon 2 by the in-frame insertion of a lacZ gene and a loxP flanked 
neomycin cassette immediately downstream of the ATG codon. Bars indicate the regions 
to which the probes used for Southern blot analysis hybridize; arrows denote the regions 
used to design the primers for genotyping. (B) Southern blot analysis of ScaI digested 
genomic DNA of selected ES cell clones hybridized with labeled DNA probes (see panel 
A) for the identification of homologous recombination. A 6.7 and 11.5kb ScaI fragment 
corresponding to the WT or targeted mutant allele, respectively, is detected in -/+ ES cell 





4.2 Generation of ZO-2-/- mice 
      Correctly targeted independent ZO-2-/+ ES cell clones were injected into C57BL/6 
blastocysts to produce chimera mice with germ line transmission of the mutated allele. 
Nine chimeric mice with ~100% Agouti coat color and a few chimeric mice with a lower 
Agouti coat were obtained. These chimeric mice were mated with either C57BL/6 or 
129Sv strain mice to establish the F1 generation of heterozygous mice. ZO-2-/+ mice 
were apparently normal and crossed to obtain homozygous animals. 
4.3 Embryonic lethality for ZO-2-/- mice 
      ZO-2-/+ male and female mice were crossed and genomic DNA was extracted from 
offspring tails and genotyped (Figure 9). ZO-2-/- pups were absent in litters from ZO-2-/+ 
crossings (Table 1), indicating embryonic lethality of ZO-2-/- mice. In order to find out at 
which stage ZO-2-/- embryos die, ZO-2-/+ mice were crossed and the pregnant mothers 
sacrificed at different stages. Embryos from E9.5-E17.5 were genotyped and no ZO-2-/- 
embryos were detected, suggesting that ZO-2-/- embryos die before E9.5. Dissection of 
embryos at E6.5, E7.5 and E8.5 revealed grossly undeveloped and abnormal embryos as 
compared to corresponding ZO-2+/+ embryos (Figure 10). Histological analysis showed 
that these abnormal embryos were much smaller than corresponding ZO-2+/+ embryos and 
apparently underwent absorption (Figure 11). Consistent with Mendelian ratios, about one 
forth of the total embryos were small and undergoing resorbtion and thus presumed to be 
ZO-2-/- (Table 1). At E8.5, the putative ZO-2-/- embryos were completely absorbed, 
whereas at E7.5, their structure was disorganized. At E6.5 and E5.5, the structure of 
putative ZO-2-/- embryos was still well organized, but growth was retarded. These findings 
thus reveal that ZO-2 is critical for embryonic development in mice.   
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Figure 9 Genotyping of transgenic mice. Genomic DNA was amplified by PCR using 
primers designed to distinguish between WT and mutant alleles. Fragment of 580 bps is 
indicative of the presence of the recombined mutant allele of ZO-2, while the 367 bps 







Figure 10 Developmental arrests of ZO-2-/- embryos. ZO-2+/+ and ZO-2-/- embryos 
dissected from their deciduas at E6.5, E7.5 and E8.5. Note the overall smaller size and 




Table 1 Genotypic analysis of offspring and embryos from crossing of ZO-2-/+ mice. 
No alive ZO-2-/- mice were not found among the offspring. About one forth of the 






Figure 11 Postimplantation development of ZO-2-/- embryos. Histology of embryos with 
normal or typical abnormal appearances at E5.5, E6.5, E7.5 and E8.5. Note the 
developmental arrest of ZO-2-/- embryos from E5.5 onwards and their eventual 
resorption by E8.5.  
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4.4 Decreased cell proliferation in ZO-2-/- embryos 
      Given the apparent smaller size of ZO-2-/- embryos, we determined if alterations in 
proliferation contributed to this developmental arrest. Bromodeoxyuridine (BrdU) was 
peritoneally injected into pregnant female mice two hours before sacrifice. E6.5 embryos 
were dissected out from the deciduas, sectioned and stained to detect BrdU incorporation. 
Based on this assay, few if any proliferating cells were found in ZO-2-/- E6.5 embryos 
when compared to ZO-2+/+ controls (Figure 12). These data suggests that decreased cell 
proliferation contributes to the retarded growth of ZO-2-/- embryos. 
 
Figure 12 Cell proliferation is compromised in E6.5 ZO-2-/- embryos. E6.5 embryos 
were labeled with BrdU and incorporated BrdU (green) and nuclei (blue) were visualized 




4.5 Increased apoptosis in E7.5 ZO-2-/- embryos 
      Given the apparent degeneration of ZO-2-/- embryos, we determined if apoptosis 
contributed to this developmental arrest. Tunnel staining was carried out on cryo-sections 
of mouse embryos from E6.5 to E8.5 to detect apoptosis. Only low levels of programmed 
cell death was detected in either ZO-2-/- or ZO+/+ embryos at E6.5. At E7.5, however, 
ZO-2-/- embryos revealed significant apoptotic activity as compared to ZO-2+/+ controls 
(Figure 13). These findings suggest that apoptosis might be a consequence of the 
decreased cell proliferation observed in ZO-2-/- embryos and not the direct cause of 
lethality for these embryos. 
 
Figure 13 Enhanced apoptosis in E7.5 ZO-2-/- embryos. Apoptosis in ZO-2+/+ and 
ZO-2-/- embryos at E6.5 or E7.5 was visualized by fluorescence microscopy using the 
Tunnel assay (red). Nuclei are stained in blue.  
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4.6 ZO-2-/- embryos do not develop mesoderm 
      Interestingly, ZO-2-/- embryos consistently failed to develop mesoderm as 
determined by histological analysis. To confirm this observation, expression of the 
mesoderm marker T-gene (brachyury) was monitored. As shown in Figure 14 (A, B), 
nuclear T-gene was detected in E7.5 ZO-2+/+ embryos but absent in ZO-2-/- embryos. In 
in vitro differentiated EBs, T-gene expression was normally expressed in ZO-2-/- EBs 
(Figure 14C). These data indicate that ZO-2-/- embryo growth is arrested before 
mesoderm formation rather than ZO-2 deficiency affecting mesoderm differentiation. 
 
Figure 14 T-gene expressions in E7.5 ZO-2-/- embryos and EBs. (A, B) T-gene antibody 
stained the mesoderm of ZO-2+/+ embryos (brown nuclei), but the staining was absent in 




4.7 Expression and localization of TJ and AJ markers is not 
affected in ZO-2-/- embryos 
      Given the role of ZO-2 protein as a scaffold that tethers TJ proteins to the 
cytoskeleton (González-Mariscal et al., 2003), we analyzed by immunostaining if the 
expression and subcellular distribution of selected TJ and AJ markers was affected. As 
shown in Figure 15 (A, D), ZO-2 was strongly expressed in ZO-2+/+ embryos at E7.5 
and particularly enriched at sites of cell-cell contact. As expected, no specific ZO-2 
staining was found in ZO-2-/- embryos. ZO-1 and ZO-3 were also expressed in E7.5 
embryos. They were predominantly found on visceral endoderm and ectoderm cells 
facing either the internal cavity or the extra-embryonic space (Figure 15B, C, E, and F). 
Neither the expression nor the distribution of ZO-3 and ZO-1 was dramatically altered in 
ZO-2-/- embryos. Furthermore, the prominent apical localization of prominin, an apical 
marker, and membrane localization of E-cadherein, a lateral marker, were maintained in 
ZO-2-/- embryos (Figure 16), indicating that the ability of TJs to maintain the asymmetric 





Figure 15 Distribution of ZO-1and ZO-3 in ZO-2-/- embryos is not altered. Sections of 
E7.5 ZO-2-/- and ZO-2-+/+ embryos were labeled with antibodies to ZO-2, ZO-1, or ZO-
3 and visualized by immunofluorescence microscopy. Ee, embryonic ectoderm; exe, 
extraembryonic ectoderm; een, embryonic endoderm; exen, extraembryonic endoderm; 
em, embryonic mesoderm; a, amnion; ac, amniotic cavity 
 
Figure 16 Apical-basal polarity is not affected in ZO-2-/- embryos. Sections of E7.5 
ZO2 -/- (A,C) and ZO-2+/+ (B,D) embryos were labeled with antibodies to the apical 
marker Prominin (A,B) or the lateral marker E-cadherin (C,D) and visualized by 
immunofluorescence microscopy. ac, amniotic cavity; ee, embryonic ectoderm; een, 
extraembryonic endoderm; ee, embryonic ectoderm; embryonic mesoderm. 
A B C
D E F 
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4.8 The TJ architecture is altered in ZO-2-/- embryos 
      To assess the structural integrity of TJs, we analyzed E6.5 and E7.5 embryo sections 
by EM. As shown in Figure 17 (A, C), the apical junctional complex were readily 
detected as electron dense plaques in ZO-2+/+ and -/+ embryos, where the intercellular 
space between adjacent visceral endoderm and ectoderm cells was obliterated. Less 
frequently, short plaques could be observed (Table 2). In contrast, long electron dense 
structures were absent in ZO-2-/- embryos and only the occasional short plaque could be 
detected (Figure 17B, D). These observations indicate that although TJ markers such as 
ZO-1 and ZO-3 still localize correctly, the structural integrity of TJs is compromised in 
the developing embryos. 
4.9 The function of TJs as a diffusion barrier is affected in 
ZO-2-/- embryos 
Given the apparent structural alterations in TJs, we monitored paracellular 
permeability in E7.5 ZO-2-/- embryos. Lanthanum permeability was efficiently restricted 
at the level of TJs in cells of control embryos (Figure 18). In contrast, lanthanum was 
readily detected in spaces between the lateral plasma membranes of adjacent cells of ZO-
2-/- embryos. Quantification showed that, whereas none of the TJs from control embryos 
allowed diffusion of lanthanum, more than 10% of the TJs from ZO-2-/- embryos were 
leaky (Table 3).Thus, the structural and functional integrity of the apical junctional 
complex was compromised in cells of developing ZO-2-/- embryos. 
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Figure 17 The architecture of the apical junctional complex is altered in cells of ZO-2-
/- embryos. A-D. E6.5 (data not shown) and E7.5 embryo sections were analyzed by TEM 
to visualize the apical junctional complex. Typical electron dense plaques were readily 
detected at the apical pole of the lateral membrane of adjacent cells of ZO-2+/+ embryos 
(A, C) but were rarely observed in cells of ZO-2-/- embryos (B, D). ZO-2-/- embryos were 






Table 2 Statistical analysis of the frequency of TJs with altered structure in ZO-2-/- 






Figure 18 The permeability barrier of the apical junctional complex is altered in cells 
of ZO-2-/- embryos. E7.5 embryos were postfixed in lanthanum nitrate and processed for 
transmission electron microscopy. Note the presence of lanthanum (arrows, black color) 















4.10 ZO-2-/- blastocysts grow normally in vitro 
Given the embryonic lethality of ZO-2-/- embryos in vivo, we analyzed whether ZO-2 
deficiency affects the growth of blastocysts in vitro. ZO-2-/+ males and females were 
mated, pregnant females sacrificed and blastocysts at E3.5 flushed from the uterus and 
cultured. As shown in Figure 19A, there was no obvious difference between ZO-2+/+ and 
ZO-2-/- blastocysts after 4 days in culture. The culture was kept for 9 days and no defect 
was observed for the ZO-2-/- cells. After 9 days in culture, cells were collected and 
genotyped (Figure 19B). Of the 68 blastocysts checked by PCR, 15 blastocysts were ZO-
2 deficient (Table 1). The number of ZO-2-/- blastocysts was about one fourth of the total 
blastocysts isolated and thus consistent with Mendelian ratio. This finding thus suggests 
that ZO-2 deficiency does not affect the survival of blastocysts. 
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Figure 19 In vitro blastocyst culture and PCR genotyping. (A) E3.5 ZO-2-/-, ZO-2-/+ or 
ZO-2+/+ blastocysts after 1 and 4 days in culture. Note the normal development of the 
inner cell mass (ICM) and trophoblast outgrowh (TG) for ZO-2-/- blastocysts. (B) 
Blastocysts were genotpyped by RT-PCR, yielding 367 bp and 580 bp fragments 





We successfully generated ZO-2-/- mice and found that these mice show early 
embryonic lethality. This finding provides the first evidence for a critical and non-
redundant role for a single ZO protein in mammalian development. In ZO-2-/- embryos, 
TJs displayed structural defects, manisfested in the absence of the electron dense apical 
junctional plaque typically observed by TEM. Experiments are currently underway to 
determine if the absence of the junctional plaque correlates with alterations in the TJ 
strands that can be observed in freeze fractures. While apical-basal polarity was not 
affected in epithelia of ZO-2-/- embryos, the barrier function of TJs was compromisd. 
However, given the loss of proliferation and the increased in apoptosis of ZO-2-/- around 
E6.5-E7.5, it is not clear whether the increased leakiness of E7.5 ZO-2-/- embryos 
reflects a bona-fide defect in the TJs or the general degradation of embryo viability. 
Intriguingly, however, in vitro studies on ZO-2-/- EBs indicated that ZO-2 is dispensable 
for normal TJ structure (e.g. the presence of an electron dense junctional plaque by TEM) 
and function (e.g. polarity and barrier) (see Chapter 9). These differences might be 
explained by the notion that minor defects in TJ structure may lead to more pronounced 
phenotypes under physiological stress. Furthermore, the relevance of individual ZO 
proteins may depend on particular tissue and/or developmental stage of the organism. 
Consistent with this speculation, silencing of ZO-2 in cell lines either shows no effect on 
TJ structure or function, only a minor delay in TJ formation (Adachi et al., 2006), or 




Chapter 5 ZO-2 rescue and phenotypic analysis 
5.1 Expression pattern of ZO-2 in early embryo 
development stage 
      ZO-2 is expressed as early as in 16-cell stage mouse embryos (Eckert et al., 2004). As 
shown in figure 20A, ZO-2 is strongly expressed in E6.5 embryos and particularly 
enriched at sites of cell-cell contact. ZO-2 staining is detected in both extra-embryonic 
and embryonic tissue and the strongest expression of ZO-2 is in the visceral endoderm. 
Similarly, ZO-2 is also expressed in ectoderm and endoderm of E7.5 embryos (Figure 
20B), but not in mesoderm. 
 
Figure 20 Expression of ZO-2 in early stage embryos. (A) ZO-2 is expressed in both 





(B) ZO-2 is expressed in both ectoderm and endoderm, but not in mesoderm (indicated 













5.2 Generation of ZO-2 chimeric embryos 
      As mentioned in Chapter 4, ZO-2 deficiency led to embryonic lethality around E6.5 
and E7.5. In order to assess whether extra-embryonic ZO-2 expression is critical for the 
embryo development, ZO-2-/- ES cells were injected into C57BL/6 blastocysts to 
produce ZO-2 chimeric embryos. One of the pregnant mothers was sacrificed at E15.5 
and embryos were dissected. Genotyping of yolk sac tissue indicated that all 6 embryos 
carried ZO-2-/- cells (data not shown). The embryos were sectioned and stained with ZO-
2 antibody. As shown in Figure 21, ZO-2 is strongly expressed in the skin of WT 
embryos but was either absent or only weakly expressed in the skin of the chimeric 
embryos. 
 
Figure 21 Expression of ZO-2 in the skin of E15.5 embryos. ZO-2 is strongly expressed 






5.3 ZO-2 is dispensable for epiblast development 
      When ZO-2 chimeric embryos where allowed to develop to term, viable mice were 
born. Table 4 summarizes the analysis of the chimeric mice derived from two 
independent ZO-2-/- ES cell clones, clone 54 (derived from the ZO2+/- ES cell used to 
generate the ZO-2+/- and ZO-2-/- mice described in Chapter 4) and clone 91. Thirty-three 
offspring were obtained from clone 54 and 17 of them had apparently 100% Agouti coat 
color. Twenty-nine offspring were obtained from clone 91, 15 of them with apparently 
100% Agouti coat color. 3 Agouti males and 1 Agouti female were crossed with C57BL/6 
WT females and males, respectively, and all 30 offspring were Agouti (Table 5). 
Genotyping indicated that all the offspring were ZO-2 heterozygotes.  
The expression of the different ZO proteins in different organs was checked by 
Western blot. As shown in Figure 22, ZO-2 expression was greatly reduced in several 
organs analyzed, while the expression of ZO-1 and ZO-3 was not visibly affected. These 
data suggest that ZO-2-/- ES cells can contribute efficiently to various tissues and ZO-2 
protein is dispensable for epiblast development. The embryonic lethality of ZO-2-/- 
embryos (see Chapter 4) may thus be due to a requirement for ZO-2 in the extra-




Table 4 Rescue of embryonic lethality by injecting ZO-2-/- ES cell into WT blastocysts. 
Two independent ZO-2-/- ES clones, #54 and #91, both gave rise to offspring with high 
percentage Agouti coat color. 
 
Table 5 Cross between chimeric mice and C57BL/6 WT mice. Both male and female 
chimeric mice gave rise to high percentage offspring with mutant allele.  
 
Figure 22 Expression of ZO proteins in chimeric mice. The expression of ZO-2 is 
greatly reduced in chimeric mice, while the expression of ZO-1 and ZO-3 is not obviously 
altered in these mice. 
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5.4 Chimeric expression of ZO-2-/- cells in testis results in 
reduced fertility of male chimeric mice 
      Mating experiments showed that male ZO-2 chimeric mice had difficulties 
impregnating C57BL/6 females. In order to assess whether the fertility of ZO-2 male 
chimeric mice was affected by the chimeric expression of ZO-2, the following mating 
experiment was carried out. One ZO-2 male chimeric mouse was paired with two 
C57BL/6 females and allowed to mate for up to 4 weeks. Once a female was identified to 
be pregnant in the course of the 4 weeks, she was separated from the male before giving 
birth to prevent a second pregnancy. As shown in Table 6, only 4 out of 8 male ZO-2 
chimeric mice were able to impregnate female mice. In contrast, all WT, ZO-2+/- 
heterozygous and ZO-2+/- chimeric male mice were able to impregnate all available 
female mice. These data shows that the fertility of male ZO-2 chimeric mice is reduced, 
likely dependent on the contribution of ZO-2-/- cells to the testis of the individual male. 
In contrast, the fertility of female ZO-2 chimeric mice was not apparently affected based 
on the results from a small scale experiment where 3 WT males were able to impregnate 


































5.5 Chimeric expression of ZO-2-/- cells in the testis results 
in apoptosis  
      Since the fertility of male ZO-2 chimeric mice was affected, we analyzed whether the 
presence of ZO-2-/- cells altered the morphology of the testis. Male ZO-2 chimeric mice 
were sacrificed from 6 to 10-months of age and the testis dissected, sectioned and stained 
with hematoxylin and eosin. As shown in Figure 23, cells were absent from several 
seminiferous tubules, resulting in empty tubules. Multiple apoptotic bodies were 
observed in several seminiferous tubules, where cells were apparently undergoing cell 
death. To assess whether the loss of cells in the seminiferous tubules was due to apoptosis, 
tunnel analysis was carried out. As shown in Figure 24, no or only an occasional 
apoptotic cell was found in seminiferous tubules of WT mice. However, extensive 
apoptosis was observed in the seminiferous tubules of ZO-2 chimeric animals, 
confirming that the observed loss of cells was due to programmed cell death. 
      In the testis, ZO-2 is expressed at the blood-testis barrier region of adjacent Sertoli 
cells (Fink et al., 2006). Immuno-staining confrimed the absence of ZO-2 at many contact 
sites of adjacent Sertoli cells in the testis of ZO-2 chimeric mice (Figure 25A). 
Expression of ZO-1 in these regions was normal (Figure 25B). As previsouly shown for 
the barrier function on TJs in embryos (Chapter 4), the lack of ZO-2 could affect the 
blood-testis barrier. This could alter the ionic environment in the different compartments 




Figure 23 Histological analysis of the testis. The cells in the testis of ZO-2 chimeric mice 
undergoing cell death and empty seminiferous tubules are indicated.  
 
 
                                   
 
Figure 24 Apoptosis in the testis of ZO-2 chimeric mice. Apoptosis signal was detected 







Figure 25 ZO-2 and ZO-1 expression in testis. (A) ZO-2 expression is greatly reduced in 
the testis of ZO-2 chimeric mice. (B) ZO-1 expression is not altered in the testis of ZO-2 
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5.6 ZO-2 chimeric mice present with defects in balance and 
hearing 
ZO-2 chimeric mice showed obvious problems in coordinated walking and often 
tilted their head to a side (Video 1). Since this behavior is typical for animals with defects 
in maintaining balance control (Torres et al., 1998), this phenotype was followed up. 
About 75% of the ZO-2 chimeric mice with 100% Agouti coat color “circled” when lifted 
by their tails (Table 7), a behavior characteristic for loss of balance control. In contrast, 
this was never observed for WT or ZO-2+/- heterozygous animals. This phenotype 
indicates that the vestibular system in the inner ear might be affected. Analysis of the 
vestibular system in these mice will be the focus of a future study.  
Defects in balance control are often linked to hearing defects. We therefore assessed 
the hearing capability of ZO-2 chimeric mice using Preyer Reflex analysis (Hulander et 
al., 1998). Briefly, a mouse kept in silent environment was subjected to a sudden sound 
by clapping the hand and the response was evaluated. Based on this test, the lack of a 
response of the animal to the sound is taken as an indication for an impairment of hearing. 
As shown in Table 8, 50% of the mice with a loss in balance control also showed hearing 
defects. A detailed analysis of the role of ZO-2 in the inner ear, in particular the 





5.7 Defects in other organs of ZO-2 chimeric mice  
In addition to testis and inner ear, other organs of ZO-2 chimeric mice showed 
obvious anomalies. These included an enlarged calyx in the kidney and an abnormal loss 
of fur (data not shown). 
 
Table 7 Balance defect in ZO-2 chimeric mice. About 70% of the ZO-2 chimeric mice (-
/ ;+/+) with high percentage Agouti coat lost balance control. ZO-2 chimeric mice (-/-
;+/+) with low percentage Agouti coat, ZO-2 chimeric mice (-/+;+/+) with high 




Table 8 Prayer Reflex analysis for hearing. For Prayer Reflex analysis, the mouse was 
kept in a silent atmosphere and was subjected to a sudden sound by clapping the hand 
and the response was evaluated. If the mouse responded, it’s judged to be normal. If not, 





ZO-2 is expressed in both embryonic and extra-embryonic tissue during the early 
developmental stages. ZO-2-/- ES cells were injected into WT blastocyst to determine 
whether ZO-2 is indispensable for both embryonic and extra-embryonic tissue based on 
the fact that injected cells only contribute to embryonic tissue but not extra-embryonic 
tissue. Surprisingly, ZO-2 chimeric mice were viable, even when ZO-2-/- cells highly 
contributed to chimeric mice based on their ~100% Agouti coat color. Furthermore, the 
injected ZO-2-/- ES cells gave rise to germ cells and most born offspring were from the 
injected ZO-2-/- ES cells. These data indicate that embryonic lethality may reflect an 
extra-embryonic requirement for ZO-2 rather than a prerequisite for development of the 
epiblast. 
In testis, the germ cells are separated from the external environment by the blood-
testis barrier (Dym et al., 1970). ZO-2 is a major component for forming the TJ in the 
blood-testis barrier, which is a highly dynamic structure. In contrast to TJs in other 
organs, TJ in the testis express both the ZO-1 alpha+ and alpha- splice forms. The 
distribution of these two isoforms, however, differs within the testis. ZO-1 alpha+ is 
restricted to TJs that join Sertoli cells to spermatogonia and preleptotene and leptotene 
spermatocytes, while ZO-1 alpha- is found in TJs between Sertoli cells to all classes of 
germ cells (Pelletier et al. 1997). In ZO-2 chimeric male mice, strong apoptosis was 
observed in the seminiferous tubules. Abnormal apoptosis might result from the 
disruption of the testis barrier. In the testis, ZO-1alpha+ expression levels are relatively 
low and other ZO proteins may not be able to compensate for the loss of ZO-2. Thus, the 
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loss of ZO-2 might result in blood-testis barrier defects, likely leading to cell death in the 
























Chapter 6 Generation and phenotypic 
analysis of ZO-3-/- mice 
6.1 Generation of ZO-3-/- mice 
     Genomic fragments containing the ZO-3 locus were isolated from a 129Sv mouse 
genomic library and subcloned into pBluescript II KS+ vector. A targeting vector 
designed to replace the exon containing the first transcriptional ATG was constructed 
using a LacZ neo cassette flanked by short and long arms of 2.2 kb and 4.8 kb for ZO-3 
(Figure 26). This insertion results in a null mutation of the corresponding gene and allows 
in principle the expression of the β-gal marker under the control of the endogenous 
transcriptional regulatory elements of ZO-3. 
      The targeting vector was linearized, electroporated into the W4 ES cells and the cells 
subjected to selection in G418. The growing clones were screened for homologous 
recombination at the ZO-3 locus by long-range PCR using the primers indicated in Figure 
26A. A band of ~ 2.5 kb was amplified for the targeted ES cell clones and 5 positive 
clones out of 96 picked were obtained (data not shown). PCR results were confirmed by 
Southern blot hybridization using the probes shown in Figure 26A. For the 5 targeted 
clones, the expected 5.8 kb wild-type and 10.6 kb mutant bands were detected, while for 
wild type clones, only one 5.8 kb wild-type band was present (Figure 26B). 
      Clone 48 and 50 were injected into C57BL/6 blastocysts to produce chimeric mice. 
Both clones produced chimeric mice with ~100% Agouti coat color and germ line 
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transmission of the mutated allele. These chimeric mice were mated with either C57BL/6 
or 129Sv strain mice to establish the F1 generation of heterozygous animals. ZO-3 
heterozygous mice were apparently normal and crossed to obtain homozygous animals.  
 
Figure 26 Targeting of the ZO-3. (A) Schematic representation of the genomic locus of 
ZO-3 shows exon 3 with the initiation ATG. The targeting vector was designed to disrupt 
exon 3 by the in-frame insertion of a lacZ gene and a loxP flanked neomycin cassette 
immediately downstream of the ATG codon. Bars indicate the regions to which probes 
used for Southern blot analysis hybridize; arrows denote the regions from where primers 
used for screening of the targeted clones were derived. 
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 (B) Southern blot of ScaI digested genomic DNA of selected ES cell clones probed with 
labeled DNA probes hybridizing to genomic DNA (see panel A) or the neomycin gene for 
the identification of homologous recombinants. a 10.6 and 5.8 kb ScaI fragment 
corresponding the targeted mutant or WT allele, respectively, is detected in targeted (+/-) 
ES cell clones, whereas only the fragment corresponding to the WT allele is present in 













6.2 ZO-3-/- mice are born and viable 
      To generate ZO-3 null mice, ZO-3-/+ male and female mice were crossed. Genomic 
DNA was extracted from the tails of offspring and genotyped. As shown in Figure 27, 
ZO-3+/+, -/+ and -/- offspring were found in the litter, in a ratio consistent with 
Mendelian inheritance (Table 9) and suggesting that ZO-3 deficiency does not affect 
embryo development. Furthermore, born mice were fully viable. In order to corroborate 
the genotype, Western blot analysis was done using tissue lysates from ZO-3+/+ and ZO-
3-/- mice (Figure 28). ZO-3 protein was absent in the lysate of liver and small intestine 
obtained from ZO-3-/- mice, thus confirming the PCR genotyping.  
 
Figure 27 Genotyping of transgenic mice. Genomic DNA was amplified by PCR using 
primers designed to distinguish between WT and mutant alleles. A fragment of 679 bps is 
indicative of the presence of the recombined mutant ZO-3 allele, while the 297 bp 
fragment denotes the WT allele.  
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Figure 28 Western blot detection of ZO-3 protein. Lysates of small  intestine and liver 
from ZO-3+/+ and ZO-3 -/- littermates were fractionated by SDS/PAGE, transferred to 




Table 9 Genotypic analysis of offspring from ZO-3-/+ mice crossing. ZO-3-/- mice are 




6.3 Organs of ZO-3-/- mice are histologically normal 
      ZO-3 is predominantly expressed in epithelial cells (Inoko et al., 2003).The tissue 
distribution of ZO-3 was monitored by Western blot analysis of selected major organs 
and ZO-3 was found to be highly expressed in stomach, intestine, liver, lung, kidney, and 
skin (Figure 29). These organs were sectioned and stained with hematoxylin and eosin. 
As shown in Figure 30, there was no histological difference detected in small intestine of 
ZO-3-/- mice. Similarly, ZO-3-/- mice monitored from birth to two years of age had no 
detectable defects in the other organs analyzed (data not shown).  
 
Figure 29 ZO-3 expressions in major mouse organ.  
 
Figure 30 H&E staining of small intestine of ZO-3-/- and ZO-3+/+ mice. Up to 24 
months of age, ZO-3-/- mice did not show any morphological differences in the intestine 
and other major organs (data not shown).  
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6.4 Expression and localization of TJ and AJ markers are 
unaffected in the small intestine of ZO-3-/- mice 
      Given the role of the ZO-3 protein as a scaffolds that tethers TJ integral membrane 
proteins to the cytoskeleton, we analyzed by immunostaining if the expression and 
subcellular distribution of selected TJ and AJ markers is affected. As shown in Figure 
31A, ZO-3 is strongly expressed in the small intestine of wild type mouse and 
particularly enriched at the apical pole of the lateral membrane of cells, facing the 
intestinal lumen. As expected, no specific ZO-3 staining was found in the small intestine 
of ZO-3-/- mice (Figure 31A). ZO-1 and ZO-2 proteins are also expressed in the small 
intestine and showed a similar distribution as ZO-3. Neither the expression nor the 
distribution of ZO-1 and ZO-2 was apparently altered in the small intestine of ZO-3-/- 
mouse (Figure 31 B, D). Similarly, the expression and distribution of occludin and E-
cadherin were not affected in the absence of ZO-3 (Figure 31D). The expression and 
localization of these proteins in other major organs such as stomach and liver was also 
analyzed and found to be similar between ZO-3+/+ and ZO-3-/- animals (data not shown). 
 93
 
Figure 31 Protein distributions in small intestine. (A) ZO-3 is not expressed in the small 
intestine of ZO-3-/- mouse; E-cadherin staining marks the lateral plasma membrane. (B, 
C, D) the distribution of ZO-1, ZO-2 and occludin is not altered in the small intestine of 






6.5 TJ architecture is intact in ZO-3 null mice 
      To assess the structural integrity of TJs, we analyzed sections of the small intestine by 
EM. As shown in Figure 32, TJs were detected as typical electron dense plaques in the 
small intestine of ZO-3+/+ mice. In contrast to the loss of the plaque observed in ZO-2-/- 
embryos (see Figure 17 of Chapter 4), no structural difference was apparent for TJs in the 
intestine of ZO-3-/- mice as compared to controls (Figure 32).  
 
Figure 32 TJ morphology. Electron micrographs of intestinal sections of ZO-3-/- and 
ZO-3+/+ mice show the presence to the typical electron dense plaques of the apical 











6.6 ZO-3 deficiency does not affect mouse growth.  
      Given the strong expression of ZO-3 in the gastrointestinal tract (e.g. stomach, small 
intestine and colon), we reasoned that defects in the epithelial tissue of these organs may 
affect nutrient uptake and postnatal growth of ZO-3-/- pups. As shown in Figure 33, 
growth rates from 2 weeks to 12 weeks of age did not differ for ZO-3+/+ and ZO-3-/- 
mice, suggesting that the digestive and absorptive functions of the gastrointestinal tract is 
not compromised in ZO-3-/- mice.  
 
Figure 33 Postnatal growth curves of ZO-3-/- and ZO-3+/+ mice. From 2 weeks to 12 



















Unlike ZO-2-/- mice, ZO-3-/- mice were viable and the different organs analyzed 
were histologically normal. This finding is consistent with a recent report (Adachi et al. 
2006). Among the three ZO proteins, ZO-3 is the shortest member and all of its 
functional domains have their corresponding sequence in ZO-1 and ZO-2. Unlike ZO-1 
and ZO-2, ZO-3 is exclusively expressed in epithelia and not in endothelia, and is also 
not present in sites of cadherin-based cell-cell adhesion (Inoko et al. 2003).  Thus, 
knockout of ZO-3 may not affect the development and viability of the mice if the 
function of ZO-3 can be compensated by ZO-1 and/or ZO-2. Alternatively, ZO-3 may be 
important for less critical physiological functions. A more detailed analysis in 
conjunction with the exposure of mice to different stress situations will likely be required 











Chapter 7 Generation and phenotypic 
analysis of ZO-2-/-ZO-3-/- mice 
7.1 Generation of ZO-2-/- ZO-3-/- mice 
      ZO-2-/+ mice were crossed with ZO-3 -/- mice to generate ZO-2-/+ZO-3-/+ mice. 
The ratio between the number of ZO-2+/+ZO-3-/+ and ZO-2-/+ZO-3-/+ offsprings was 
about 1:1, consistent with Mendelian ratio (data not shown). ZO-2-/+ZO-3-/- mice were 
obtained by crossing ZO-2-/+ZO-3-/+ mice, but as expected, no ZO-2-/-ZO-3-/- animals 
were found. ZO-2-/+ZO-3-/- mice were crossed and the ratio between the number of ZO-
2+/+ZO-3-/- and ZO-2-/+ZO-3-/- offsping was around 1:2, consistent with Mendelian 
ratio (Table 10). Several pregnant mothers were sacrificed at different stages to obtain 
embryos. Similar to ZO-2-/-, ZO-2-/-ZO-3-/- embryos died at an early embryonic stage.  
 





7.2 ZO-2-/+ZO-3 -/- mice are histologically normal 
      ZO-2-/+ZO-3-/- mice were born and viable. Main organs, including liver and lung, 
were dissected from mice aged between 2 to 24 months and their histology was analyzed. 
As shown in Figure 34, there were no obvious histological differences between ZO-2-
/+ZO-3-/- and WT mice in the liver and lung. Also other major organs of ZO-2-/+ZO-3-/- 
animals, in particular intestine and kidney, were normal (data not shown). In order to 
assess whether upregulation of the expression of other ZO family members was 
responsible for functional redundancy, protein expression levels for the different ZO 
proteins was quantified in WT, ZO-2-/+, ZO-3-/-, and ZO-2-/+ZO-3-/- mice (Figure 35). 
ZO-2 expression levels were downregulated in ZO-2-/+ and ZO-2-/+ZO-3 -/- mice, but 
not changed in ZO-3-/- mice. As expected, ZO-3 was not expressed in ZO-3-/- and ZO-2-
/+ZO-3 -/- mice, but its expression was unchanged in ZO-2-/+ animals. ZO-1 expression 
was similar in WT, ZO-2-/+, ZO-3-/-, and ZO-2-/+ZO-3-/- mice. These data suggest that 
ZO proteins either do not compensate for each other or that compensation does not 
require increased expression levels. 
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Figure 34 Histological analysis of ZO-2-/+ZO-3-/- mice. No histological abnormality 




Figure 35 Western blots for ZO protein expression. ZO protein expression in liver and 




7.3 ZO-2-/-ZO-3-/- embryos die earlier than ZO-2-/- 
embryos 
      In order to determine the embryonic stage at which ZO-2-/-ZO-3-/- embryos die, ZO-
2-/+ZO-3-/- mice were crossed and the pregnant mothers sacrificed at E6.5 and E7.5. 
Approximately one fourth of the deciduas dissected at E6.5 and E7.5 were small in size 
as compared to control deciduas (Table 11). Histological analysis showed that these 
deciduas were empty (Fig. 36) and did not contain small embryos as found for deciduas 
from the crossing of ZO-2-/+ mice (see Chapter 4), although empty deciduas were also 
occasionally observed in crossings of ZO-2-/+ mice, these were of normal size. These 
data indicate that ZO-2-/-ZO-3-/- embryos die earlier than ZO-2-/- embryos and thus ZO-
3 might partially compensate a function of ZO-2 required during early stages of embryo 
development. 
 
Table 11 Statistical analysis of embryo morphology (normal or small and undergoing 
absorption) at E6.5 and E7.5. While some ZO-2-/- embryos appear to survive up to E7.5, 
no ZO-2-/-ZO-3-/- embryos survive past E6.5.  
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Figure 36 Histological analysis of ZO-2-/-ZO-3-/- embryos. The ZO-2-/-ZO-3-/- 
embryos are completely absorbed by E6.5.  
 
7.4 ZO-2-/- ZO-3-/- blastocysts grow normally in vitro 
      Given the early embryonic lethality of ZO-2-/-ZO-3-/- embryos in vivo, we analyzed 
whether ZO-2 and ZO-3 deficiency affected the growth of blastocysts in vitro. ZO-2-
/+ZO-3-/- male and female mice were crossed, pregnant mothers sacrificed at E3.5 and 
blastocysts flushed out from the uterus. As shown in Figure 37, there was no obvious 
difference in growth of ZO-2+/+ZO-3-/-, ZO-2-/+ZO-3-/-, and ZO-2-/-ZO-3-/- 
blastocysts after 4 days culture. The culture was kept for up to 9 days and again no 
obvious difference among the cultures was observed (data now shown). After 9 days in 
culture, cells were collected and genotyped. 18 blastocysts were checked by PCR and 4 
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blastocysts were ZO-2 and ZO-3 deficient (Figure 38). The number of ZO-2-/-ZO-3-/- 
blastocysts was about one fourth of the total blastocysts and thus consistent with 
Mendelian inheritance. These data thus indicate that ZO-2 and ZO-3 deficiency does not 
affect the growth of blastocysts in vitro. 
 
Figure 37 In vitro culture of blastocysts. ZO-2+/+ZO-3-/-, ZO-2-/+ZO-3-/-, and ZO-2-/-




Figure 38 Statistical analysis of the number blastocysts in different genotype.  The 
number of ZO-2+/+ZO-3-/-, ZO-2-/+ZO-3-/-, and ZO-2-/-ZO-3-/- blastocysts obtained 





In order to assess whether ZO-2 and ZO-3 can compensate for each other, ZO-2+/- 
heterozygous and ZO-3-/- homozygous mice were crossed. As expected, ZO-2-/-ZO-3-/- 
mice were embryonic lethal. However, the ZO-2-/-ZO-3-/- embryos died earlier than ZO-
2-/- embryos and no ZO-2-/-ZO-3-/- embryos were found at E6.5. Smaller empty 
deciduas were found, indicating that ZO-2-/-ZO-3-/- blastocysts were implanted but died 
shortly after implantation. As discussed above, ZO-2 is likely indispensable for the 
normal function of the extra-embryonic tissue but dispensable for the growth of epiblast. 
ZO-3 is highly expressed in the extra-embryonic tissue (data not shown). Since ZO-2-/-
ZO-3-/- embryos died earlier than ZO-2-/- embryos, ZO-3 might partially compensate for 
the function of ZO-2 in extra-embryonic tissue at early stages of embryonic development. 
ZO-2-/-ZO-3-/- blastcysts grew normally in vitro, suggesting that ZO-2 and ZO-3 are 
dispensable for blastocyst development prior to implantation.  
We can not exclude that ZO-2 and ZO-3 could also compensate for each other at 
later stages of embryonic development and/or during postnatal life. Derivation of 
chimeric mice from ZO-2-/-ZO-3-/- ES cell could be a possible approach to further 
explore the roles of ZO-2 and ZO-3 at those later stages. 
ZO-2 expression levels were reduced by ~50% in the mice carrying one inactivated 
allele. Furthermore, ZO-3 partially compensated for the function of ZO-2 during the early 
embryonic development stage. Therefore, although both ZO-2 heterozygous and ZO-3 
homozygous mice were phenotypically normal, it was interesting to analyze the 
phenotype of ZO-2-/+ZO-3-/- mice. Phenotypic analysis in terms of survival, health and 
fertility showed that ZO-2-/+ZO-3-/- mice were viable and indistinguishable from WT 
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mice. Western blot analysis indicated that ZO-2 expression levels were reduced by half 
and ZO-1 expression levels were not altered in ZO-2-/+ZO-3-/- mice. These data thus 
show that even in the absence of ZO-3, half the ZO-2 protein levels might be sufficient 





















Chapter 8 Phenotypic analysis of ZO-1-/- 
embryonic stem cells 
8.1 Protein expression in ZO-1-/- EBs 
      Given the strong expression of ZO-1 protein in EBs, the expression levels of other TJ 
and AJ markers were analyzed by Western blot. ES cells were differentiated to form EBs 
and on day 10, EBs were lysed and the expression of selected proteins analyzed. As 
expected and shown in Figure 39, ZO-1 was not expressed in ZO-1-/- and downregulated 
in ZO-1-/+ EBs. The expression of ZO-2 was not significantly affected but, interestingly, 
ZO-3 protein levels were reduced in ZO-1-/- EBs. The expression levels of occludin, 
cingulin, E-cadherin and claudin-3 were not altered in either ZO-1-/+ and ZO-1-/- EBs. 
These data show that expression of ZO-3, but not that of ZO-2 or the other junction 









Figure 39 Expression levels of selected junction-associated proteins in ZO-1-/- EBs. 
Western blot was done on lysates from day 10 EBs to assess the expression of ZO 
proteins and selected TJ and AJ markers. ZO-1 was not expressed in ZO- -/- EBs and 
downregulated in ZO- -/+ EBs; ZO-3 was downregulated in ZO-1 -/- EBs, while the 
expression of ZO-2 and the other TJ and AJ markers analyzed was not altered in either 





8.2 The subcellular localization of several TJ and AJ 
markers is altered in ZO-1-/- EBs 
      Given the role of ZO-1 as a scaffold protein that links TJ proteins to the cytoskeleton, 
we analyzed by immunostaining if the subcellular distribution of selected TJ and AJ 
markers was affected. As shown in Figure 40A, ZO-1 was strongly expressed in the 
epithelia of ZO-1+/+ EBs, where it was enriched at sites of cell-cell contact. As expected, 
no specific ZO-1 staining was observed in ZO-1-/- EBs (Figure 40A). EBs also expressed 
ZO-2, ZO-3 and other TJ and AJ markers such as occludin and cingulin. While ZO-2 
remained well localized to the sites of cell-cell contact in the epithelia or ZO-1-/- EBs, 
ZO-3 showed a diffused distribution (Figure 40B, C). The localization of occludin and 
cingulin was not altered in the epithelia of ZO-1-/- EBs (Figure 40D, 4E). Claudin-1, 
claudin-3, claudin-4, claudin-5, claudin-6 and claudin-7, however, no longer showed 
plama membrane localization but instead were diffused throughout the cytoplasm (Figure 
40F, G, H, I, J, K). The localization of the apical maker moesin and the lateral marker E-
cadherin was unaffected in ZO-1-/- EBs (Figure 41), indicating that the ability of TJs to 
maintain the asymmetric distribution of proteins between the apical and the basolateral 















































Figure 40 Distribution of ZO proteins, TJ and AJ markers in ZO-1-/- EBs. (A) ZO-1 is 
not expressed in ZO-1-/- EBs. (B) Distribution of ZO-2 is not altered. (C) ZO-3 is 
diffused to the cytoplasm in ZO-1-/- EBs. (D, E) Distribution of occludin and cingulin is 
not alterd. (F, G, H, I, J, K) Claduin-1, claudin-3, claudin-4, claudin-5, claudin-6 and 
claudin-7 are diffused to the cytoplasm in ZO-1-/- EBs. 
 
 
Figure 41 Apico-basolateral polarities are not affected in ZO-1-/- EBs. Sections of day 
15 ZO-1-/- and ZO-1+/+ EBs were labeled with antibodies to the apical marker moesin 




8.3 The TJ structure is affected in ZO-1-/- EBs 
      To assess the structural integrity of TJs, we analyzed sections of 5-day and 10-day 
EBs by EM. As shown in Figure 42A, the apical junctional complex was readily detected 
as electron dense plaques in ZO-1+/+ EBs, where the intercellular space between 
adjacent epithelial cells was obliterated. However, in ZO-1-/- EBs, distinct TJ plaques 
were rarely detected. Quantification by counting the presence of well established plaques 
between adjacent cells revealed that they were present at ～100% of the cell-cell contact 
sites in ZO-1+/+ EBs, but only at ~13% of the contacts between cells in ZO-1-/- EBs 
(Figure 42B). These data indicate that ZO-1 deficiency affects the formation of well 












Figure 42 The architecture of the apical junctional complex is altered in cells of ZO-1 
-/- EBs. (A) Day 10 EBs were sectioned and analyzed by TEM to visualize the apical 
junctional complex. Typical electron dense plaques were readily detected at the apical 
pole of the lateral membrane of adjacent cells of ZO-1+/+ EBs, but were rarely observed 







8.4 ZO-1 deficiency promotes mesoderm development 
     ZO-1 has been implicated in the regulation of cell proliferation and differentiation. To 
determine if the absence of ZO-1 had an effect on gene expression and to elucidate 
possible signaling pathways affected, we embarked on microarray analysis of day 10 ZO-
1+/+ and ZO-1-/- EBs. Interestingly, and as shown in Table 12, genes related to 
mesoderm development were strongly upregulated. The mRNA level of the mesoderm 
marker T-gene/Brachyury, for example, was more than 20-fold higher in ZO-1-/- as 
compared to ZO-1+/+ EBs. Furthermore, the genes involved in Wnt signaling were also 
upregulated. In order to confirm the microarray results, RT-PCR was used to check the 
expression of T-gene. As shown in Figure 43A, T-gene mRNA expression was much 
higher in ZO-1-/- EBs. Western blots indicated that T-gene was also upregulated at the 
protein level (Figure 43C). These data suggest that ZO-1 might be involved in the 
regulation of gene expression during the early stages of embryo development and ZO-1 
deficiency facilitates mesoderm development. 
8.5 ZO-1deficiency promotes mesoderm development via a
β–catenin/Wnt dependent signaling pathway. 
      ZO-1 indirectly interacts with β–catenin (Itoh et al., 1997), which is a central player 
in the Wnt signaling pathway. Furthermore, Wnt proteins regulate the expression of T-
gene. To assess whether the upregulation of T-gene in the ZO-1-/- EBs involves the β–
catenin/Wnt signaling pathway, β–catenin expression levels were analyzed by Western 
blot. This analysis revealed that total β–catenin protein levels were the same in ZO-1+/+, 
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ZO-1-/+ and ZO-1-/- EBs. β –catenin can be present in an inactive form and a 
phosphorylated active form (Sinha et al., 2004). Since only the ser33/ser37 
phosphorylatyed form can activate Wnt signaling (Sinha et al., 2004), we used a 
phospho-specifc antibody against with phospho-amino acid ser33/ser37 to monitor the 
activation state of β–catenin in the different EBs. Interestingly, phosphorylatedβ–
catenin levels were significantly upregulated in ZO-1-/- as compared to ZO-1+/+ EBs 
(Figure 43C). As a positive control, 293T cells were treated with LiCl, which is known to 
activate β–catenin (Figure 43B).  
Thus, the absence of ZO-1 results in increased levels of activeβ–catenin, likely 
resulting in the activation of the Wnt signaling pathway and the upregulation of the 
expression of genes involved in mesoderm development, including T-gene. 
 
Figure 43 ZO-1 deficiency results in the upregulation of T-gene expression. (A), RT-
PCR showed upregulation of T-gene mRNA in day 10 ZO-1-/- EBs. (B), An antibody 
specific for the activated form of β-catenin antibody detcts increased levels of activated 
β –catenin in 293T cells treated with LiCl. (C), T-gene and active β-catenin are 





Table 12 Microarray analysis. Microarray analysis to detect the expression levels of 





8.6 EBs derived from ZO-1-/- ES cells have a larger 
volume compared to ZO-1+/+ EBs. 
      We observed that on average the volume of ZO-1-/- EBs was larger than that of ZO-
1+/+ EBs (Figure 44A). In additions, ZO-1-/- EBs displayed a smoother surface and 
appeared darker than ZO-1+/+ EBs. To assess whether the ZO-1-/- EBs contained more 
cells as compared to ZO-1+/+ controls, EBs were cultured in hanging drops. On day 5, 50 
EBs each were randomly picked, trypsinized and the number of cells counted. As shown 
in Figure 44B, the 50 ZO-1-/- EBs contained on average ~1.5 fold more cells than an 
equal number of ZO-1+/+ EBs.  
To determine if the higher number of cells in ZO-1-/- EBs was the result of an 
increased cell proliferation rate, BrdU incorporation was monitored in day 5 EBs. Indeed, 
as shown in Figure 44C, BrdU incorporation was enhanced in ZO-1-/- as compared to 
ZO-1+/+ EBs, suggesting a higher cell proliferation rate in the absence of ZO-1. The 




Figure 44 Proliferation of ZO-1-/- EBs. (A) ZO-1-/- EBs are larger than ZO-1+/+ EBs. 






















Analysis of selected proteins showed that the expression levels of some were altered 
in ZO-1-/- EBs. For example, ZO-3 was downregulated. In addition, the membrane 
localization of ZO-3 and several claudins was disturbed. Furthermore, EM analysis 
indicated that the TJs were either not well developed or absent in ZO-1-/- EBs. Our 
findings differ from those of a recent report, in which ZO-1 was demonstrated to be 
dispensable for TJ function in Eph 4 epithelial cells (Umeda et al. 2004). In ZO-1-/- Eph4 
cells, TJ plaques were indistinguishable from those of WT Eph4 cells and only the 
recruitment of a few proteins to TJs was delayed. Furthermore, the localization of TJ 
proteins was not changed in ZO-1-/- Eph4 cells, with the sole exception of cingulin, 
which was diffused in the cytoplasma. In contrast, cingulin still localizes to the plasma 
membrane in ZO-1-/- EBs. The differences observed between ZO-1-/- EBs and ZO-1-/- 
Eph4 cells might be due to the distinct nature of these two cell lines. First, EBs are 
derived from ES cells, while Eph4 cells are a cancer cell line. Normal and cancer cells 
may display different properties, in particular with respect to cell-cell adhesion. Second, 
different protein sets are expressed in EBs and EpH4 cells. For example, ZO-3 is 
expressed in EBs but absent from Eph4 cells (Umeda et al., 2006). Different expression 
patters are also found for claudins (González-Mariscal et al., 2003), among other proteins. 
Third, Eph4 cells have at least four alleles for ZO-2 (Umeda et al. 2006), while EBs are 
diploid. Finally, EB formation recapitulates early stages of embryonic development with 
its dynamic regulation of gene expression, whereas Eph4 cells represent fully 
differentiated epithelial cells. Thus, at least during the development of EBs from ES cells, 
ZO-1 is critical for the integrity of epithelial TJs. 
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After 5 days in culture ZO-1-/- EBs were significantly larger than WT EBs. BrdU 
incorporation experiments revealed that cell proliferation was enhanced as compared to 
control EBs. On the other hand, apoptotic activity in ZO-1-/- EBs remained similar to that 
in WT EBs. These findings suggest that ZO-1 plays a crucial role in cell cycle regulation. 
Previous reports revealed that ZONAB regulates cell proliferation by controlling PCNA 
and cyclin D1 expression and that ZO-1 can influence the activity of ZONAB by 
sequestering it to the plasma membrane (Balda et al. 2000). However, based on Western 
blot and immunoflurescence analysis, we found no evidence for altered ZONAB 
expression levels or ZONAB localization in ZO-1-/- EBs (data not shown). Furthermore, 
microarray analysis showed that the expression of PCNA and cyclin D1 is not affected in 
ZO-1-/- EBs. Based on preliminary RT-PCR analysis, cyclin D2 appears to be strongly 
upregulated in ZO-1-/- EBs (data not shown). These data indicate that ZO-1 might 
regulate cell proliferation in EBs independent of ZONAB. 
In ZO-1-/- EBs, expression of the mesoderm maker T-gene/brachyury was 
upregulated at both the mRNA and protein levels. T-gene is regulated by the Wnt/β-
catenin pathway (Yamaguchi et al. 1999; Kemler et al. 2004; Chen et al. 2006). Although 
there is not evidence for a direct interaction of ZO-1 with β-catenin, ZO-1 can interact 
with α-catenin to form a complex with E-cadherin andβ-catenin (Itoh et al.1997). More 
interestingly, however, mislocalization of intact ZO-1 to the cytosol in breast cancer cell 
lines lacking occludin (Polette et al., 2005) or overexpression of ZO-1 mutants that do not 
associate with the plasma membrane (Reichert et al., 2000) has been shown to activate 
β-catenin/Tcf/Lef transcriptional activity. Thus, ZO-1 might be able to regulateβ -
catenin indirectly. Although the protein expression level and localization of β-catenin 
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was not affected in ZO-1-/- EBs, more of the active, Ser33/Ser37 phosphorylated form of 
β-catenin, was found. Therefore, ZO-1 deficiency may favor β-catenin phosphorylation, 
resulting in the activation of canonical Wnt signaling and upregulation of T-gene 
expression. In contrast to EBs, silencing of β-catenin via siRNA in breast cancer cells 
abrogated β-catenin signaling, suggesting differences between EBs and cancer cell lines 
which will be explored in future studies. These findings however confirm that ZO-1 is 
not only involved in TJ formation, but also play a crucial regulatory role in cell 















Chapter 9 Generation and phenotypic 
analysis of ZO-2-/- embryonic stem cells 
9.1 Generation of ZO-2-/- ES cells 
      To obtain ZO-2-/- ES cells, previously generated ZO-2-/+ ES cells (see Chapter 4) 
were selected with 20 mg/ml G418 and screened by PCR (Figure 45A). The ZO-2+/+ ES 
cell clones displayed only the WT band of 254 bps; the ZO-2-/+ ES cell clones had both 
WT and mutant bands, and the ZO-2-/- ES cell clones had only the mutant band of 368 
bps. The ZO-2 deficiency was confirmed by Western blot (Figure 45B). All three ZO 
proteins were expressed in control ES cells. ZO-2 expression was reduced in ZO-2-/+ ES 
cells and absent in ZO-2-/- ES cells. The expression of ZO-1 and ZO-3 was not 
significantly different in ZO-2+/+, -/+ and -/- ES cells. ZO-2-/- ES cells were 







Figure 45 Generation of ZO-1 -/- ES cell lines. (A) Six different ES cell clones were 
genotyped. ZO-1+/+ clones only present the WT band(254 bps), ZO-1-/+ clones yield 
both the WT and mutant band(368 bps), and ZO-1-/- clones only have the mutant band.(B) 
Western blot was done on lysates from 6 ES cell lines to access the expression of ZO-1, 
ZO-2, and ZO-3. ZO-1 was not expressed in ZO-1-/- ES cell lines and downregulated in 
ZO-1 -/+ ES cell lines, while the expression of ZO-2 and ZO-3 was not altered in ZO-1 -
/- and ZO-1 -/+ ES cell lines. (C) Morphology of ZO-1 -/- ES cells was similar to that of 











9.2 Normal expression levels of TJ and AJ markers in ZO-2 
-/- EBs 
      Given the strong expression of ZO-2 protein in the EBs (Figure 46, 47A), expression 
levels of selected TJ and AJ markers in ZO-2 -/- EBs were analyzed by Western blot. 
Protein was extracted from ES cells differentiated into EBs for either 5 or 10 days. All 
three ZO proteins were expressed in EBs (Figure 46). ZO-2 was absent in ZO-2-/- and 
downregulated in ZO-2-/+ EBs. The expression of ZO-1 and ZO-3 was not significantly 
changed on either day 5 or 10 in ZO-2+/+, -/+ or -/- EBs. Also the expression of other 
junction proteins such as occludin and cingulin was not changed in ZO-2 -/- EBs (Figure 
46). These data suggest that ZO-2 deficiency does not affect the expression levels of the 
TJ and AJ markers analyzed. 
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Figure 46 Protein expressions in ZO-2-/- EBs. Western blot analysis was done on 
lysates of day 10 EBs to access the expression of ZO proteins and TJ and AJ markers. 
ZO-2 was not expressed in ZO-2 -/- EBs and downregulated in ZO-2 -/+ EBs. The 
expression of ZO-1, ZO-3 and the other TJ and AJ markers indicated was not altered in 
either ZO-2 -/- or ZO-2 -/+ EBs. The expression of occludin, cingulin, E-cadherin, 







9.3 Normal localization of selected TJ and AJ markers in 
epithelia of ZO-2-/- EBs 
 Given the role of ZO proteins as scaffolds that tether TJ proteins to the cytoskeleton, 
we analyzed by immunostaining if the subcellular distribution of selected junction 
markers was affected. As shown in Figure 47A, ZO-2 was strongly expressed in the 
epithelia of ZO-2+/+ EBs and particularly enriched at sites of cell-cell contact. As 
expected, no specific ZO-2 staining was found in ZO-2-/- EBs. ZO-1, ZO-3 and the other 
TJ and AJ markers analyzed, including occludin and E-cadherin, were also expressed in 
the epithelia of EBs (Figure 47B, C, D, F, and G). None of these proteins was 
mislocalized in ZO-2 -/- EBs. Furthermore, the prominent apical localization of moesin 
was maintained in ZO-2-/- EBs (Figure 48). This, together with the lateral localization of 
E-cadherin, indicated that the ability of TJs to maintain the asymmetric distribution of 


















Figure 47 Distribution of ZO proteins and selected TJ and AJ markers in ZO-2-/- EBs. 
(A) ZO-2 is not expressed in ZO-2-/- EBs and the distribution of E-cadherin is not altered. 
(B, C, D, E, F, G) The distribution of ZO-1, ZO-3, occludin, cingulin, claudin-1 and 
claudin-3 is not affected in ZO-2-/-  
 
 
Figure 48 The apico-basolateral polarity is not affected in ZO-2-/- EBs. Sections across 






9.4 The TJ structure and function are unaffected in ZO-2-/- 
EBs 
      To assess the structural integrity of TJs, we analyzed day 5 and day 10 EBs sections 
by EM. As shown in Figure 49A, apical junctional complexes were readily detected as 
electron dense plaques, where the intercellular space between adjacent epithelial cells 
was obliterated. In both ZO-2+/+ and ZO-2 -/- EBs, the TJ plaques were well developed.  
      Permeability analysis was done to assess the TJ integrity by monitoring lanthanum 
nitrate leakage in ZO-2+/+ and ZO-2-/- EBs (Figure 49B). Lanthanum did not penetrate 
into ZO-2+/+ or ZO-2-/- EBs, indicating an intact paracellular barrier. As a control, WT 
EBs were pretreated with EDTA, which is known to disrupt TJs. In this case, lanthanum 
leaked into the EBs and could be readily detected in the intercellular space of adjoining 
cells. In summary, these data indicate that ZO-2 deficiency does no affect the structural 

















Figure 49 The architecture and permeability barrier of the apical junctional complex 
are not altered in cells of ZO-2 -/- EBs. (A) Day 10 EBs were sectioned and analyzed by 
TEM to visualize the apical junctional complex. Typical electron dense plaques were 
readily detected at the apical pole of the lateral membrane of adjacent cells in both ZO-
2-/- and ZO-2+/+ EBs (B) Day 10 EBs were postfixed in lanthanum nitrate and 
processed for transmission electron microscopy. Note the presence of lanthanum in 







9.5 ZO-2-/- EBs are of a larger size as compared to that of 
ZO-2+/+ EBs.  
ZO-2 -/- EBs were found to be larger than ZO-2+/+ EBs (Figure 50A). To assess the 
cause for formation of larger EBs, cell numbers were monitored in cultures transferred 
from a 2 day hanging drop in differentiation media into suspension. From day 1 in 
suspension culture onwards, 10 EBs were randomly picked, trypsinized and the cell 
numbers determined by counting (Figure 50B). While the cell number in ZO-2+/+ and 
ZO-2 -/- EBs was initially similar, it then increased faster in ZO-2 -/- EBs during the 
following days in culture. By day 8, ZO-2-/- EBs were much larger than ZO-2+/+ EBs 
and the cell number was about twice that of controls. This analysis indicates that either 
increased cell proliferation or reduced cell death contribute to the formation of larger 






Figure 50 Volume of ZO-2-/- EBs. (A) ZO-2-/- EBs are larger than ZO-2+/+ EBs. (B) 







ZO-2-/- ES cells were generated to analyze the role of ZO-2 in TJ function in EBs. 
The protein expression levels and membrane localization of several selected TJ and AJ 
markers were not affected. The electron dense plaque of the apical junctional complex 
observed by TEM was intact in ZO-2-/- EBs. Furthermore, apical-basolateral polarity and 
the barrier to lanthanum diffusion were not altered in ZO-2-/- EBs. Since ZO-1 and ZO-3 
are highly expressed in the epithelia of EBs, they might compensate for the function of 
ZO-2. Consistently, visceral endoderm epithelial-like ZO-3-/- cells derived from F9 
teratocarcinoma retain a normal molecular TJ architecture in the absence of ZO-2 
expression (Adachi et al. 2006). Therefore, at least in EBs cultured in vitro, ZO-2 is 
dispensable for the establishment of functional TJs. Interestingly, however, both the 
structure and barrier function of TJs was compromised in ZO-2-/- E7.5 embryos (see 
Chapter 4). As discussed above, this may reflect the fact that embryos are exposed to 
“physiological stress”, which could affect the robustness of TJs in the absence of ZO-2. 
Alternatively, the obaserved strucutal and functional defects of TJs observed in embryos 
may be a consequence of the observed deterioration of ZO-2-/- embryos around E6.5-7.5 
as evidenced by a decreased proliferation and an enhanced apoptosis. 
Cultured ZO-2-/- EBs were larger than WT EBs. Preliminary data indicates an 
upregulation of cyclin D1 expression in ZO-2-/- EBs (data not shown), consistent with a 
recent report that ZO-2 transcriptionally downregulates cyclin D1 (Huerta et al., 2007). 
ZO-2 has also been shown to associate with several transcription factors in epithelial cells, 
including Jun and Fos (Betanzos et al. 2004). In sparse cultures, Jun and Fos colocalize 
with ZO-2 both in the nucleus and at the plasma membrane of MDCK cells. Once cells 
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reach confluence, Jun and Fos proteins are exclusively present at the plasma membrane. 
Since Jun and Fos are regulators of cellular proliferation, transformation and death 
(Shaulian et al. 2002), the lack of ZO-2 might affect the regulation of Jun and Fos activity 

















Chapter 10 Generation and phenotypic analysis 
of ZO-1-/-ZO-2-/- ES cells 
10.1 Generation of ZO-1-/-ZO-2-/- ES cells 
      To generate ES cells carring both inactivated ZO-1 and ZO-2 genes, the previously 
described ZO-1-/- ES cells (see Chapter 3) were transfected with cre-recombinase 
expression vector (Taniguchi et al. 1998) to delete the floxed Neo gene present in the 
mutant ZO-1 allele. Cells were selected in puromycin for the presence of the cre-plasmid 
and surviving clones screened for the deletion of the Neo gene based on their sensitivity 
to G418. G418 sensitive clones were expanded and those that had lost the cre-plasmid 
were identified by their sensitivity to puromycin. These ES cell clones were then used to 
inactivate the ZO-2 gene using the targeting vector described in Chapter 9. Inactivation of 
both the ZO-1 and ZO-2 genes was confirmed by Western blot analysis (Figure 51A), 
leading to the identification of six independent ZO-1-/-ZO-2-/- ES cell clones. These ZO-







Figure 51 Characterization of ZO-1-/-ZO-2-/- ES cells. (A) ZO-1 and ZO-2 are not 
expressed in ZO-1-/-ZO-2-/- ES cell. The expression of ZO-3 is not altered. (B) ZO-1-/-












10.2 Protein expression in ZO-1-/-ZO-2-/- EBs 
      Given the strong expression of ZO-1 and ZO-2 proteins in wild-type EBs, expression 
levels of different TJ and AJ markers was analyzed by Western blot in ZO-1-/-ZO-2-/- 
EBs. As expected, neither ZO-1 nor ZO-2 was expressed in ZO-1-/-ZO-2-/- EBs (Figure 
52). As observed for ZO-1-/- EBs, ZO-3 was also downregulated in ZO-1-/-ZO-2-/- EBs. 
The expression levels for occludin, cingulin, E-cadherin and claudin-3 did not differ 
significantly between WT, ZO-1-/-, ZO-2-/- and ZO-1-/-ZO-2-/- EBs (Figure 52).  
 
Figure 52 Protein expressions in ZO-1-/-ZO-2-/- EBs. ZO-1 and ZO-2 are not expressed 
in ZO-1-/-ZO-2-/- EBs. The expression of ZO-3 is downregulated in ZO-1-/- and ZO-1-/-
ZO-2-/- EBs. The expression of occludin, cingulin, E-cadherein and claudin-3 is not 
altered in ZO-1-/-ZO-2 EBs. 
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10.3 The volume of ZO-1-/-ZO-2-/- EBs is larger as 
compared to that of WT EBs. 
      The volume of ZO-1-/-ZO-2-/- EBs was larger when compared to their WT 
counterparts (Figure 53A) and their surface had a smoother appearance. I therefore 
assessed cell growth in the EBs using hanging drop cultures. At different times (3-10 
days) in hanging drop culture, 10 EBs were picked, trypsinized and the number of cells 
counted. As shown in Figure 53, the cell number in ZO-1-/-ZO-2-/- EBs increased faster 
over time as compared to WT EBs. On day 10, 10 pooled ZO-1-/-ZO-2-/- EBs contained 










Figure 53 Morphology and cell growth curve of ZO-1-/-ZO-2-/- EBs. (A) Day 5 ZO-1-/-
ZO-2-/- EBs have a larger volume than WT EBs. ZO-1-/-ZO-2-/- EBs have a smooth 
surface and are regular in shape. (B) ZO-1-/-ZO-2-/- EBs consist of more cells at any 





10.4 ZO-1/ZO-2 double knockout affects cell attachment 
and migration. 
 The smoother appearance of the surface observed in ZO-1-/-ZO-2-/- EBs (Figure 53) 
may reflect differences in structure and/or composition of the plasma membrane and 
affect the attachment and migration of the cells. To monitor cell attachment and migration, 
cells were transferred from a 2 day drop culture into suspension culture in bacterial dishes 
for 5 days and then seeded into 24-well tissue culture plates. After two days, +/+, ZO-1-/- 
and ZO-2-/- EBs attached to the bottom of the tissue culture plate and the cells spread out 
from the EBs. In contrast, both attachment and speading of cells from ZO-1-/-ZO-2-/- 
EBs were significantly delayed (Figure 54A). The cells of ZO-1-/-ZO-2-/- EBs showed 
extended spreading only around day 5 and they formed smaller colonies (Figure 54B). 
These data strongly suggest that cell attachment, cell migration and cell proliferation are 
affected in EBs lacking both ZO-1-/- and ZO-2-/-. 
 In order to analyze in more detail the surface of ZO-1-/-ZO-2-/- EBs, EBs 
transferred from 2 day hanging drop culture into 5 day suspension culture were subjected 
to scanning electronic microscopy. ZO-1-/-ZO-2-/- EBs had apparent discontinuities in 
the surface cell layer and the cells had a more fibroblastic appearance, obviously different 
from WT, ZO-1-/- or ZO-2-/- EBs (Figure 55). These changes in the surface and the cell 
morphology observed for ZO-1-/-ZO-2-/- EBs may thus explain their compromised 
attachment and migration. 
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Figure 54 Morphology of EBs after 2 days and 5 days culture on normal cell culture 
plates. The cells of +/+, ZO-1-/- and ZO-2-/- EBs attached to the bottom and spread out, 
while both attachment and spreading of cells from ZO-1-/-ZO-2-/- EBs were delayed (A) 





Figure 55 Scanning electron microscopy of day (2+5) EBs. The surface of ZO-1-/-ZO-2 





As discussed above, both ZO-1-/- and ZO2-/- deficiency lead to larger EBs. As 
expected, also ZO-1-/-ZO-2-/- EBs were larger than WT EBs, but their volume was not 
increased as compared to that of single knock-out EBs, consistent with the two proteins 
playing a role in a common pathway. When ZO-1-/-ZO-2-/- EBs were transferred to 
normal cell culture plates for 2 days, WT EBs were flat and their cells spread, whereas 
ZO-1-/-ZO-2-/- EBs remained spherical in shape and the cells did not spread. Given the 
well established role of actin in cell migration (Suetsugu et al. 2003) and the known 
interaction of ZO-1 and ZO-2 with filamentous actin (Fanning et al., 1998; Wittchen et al., 
1999), a role for ZO-1 and/or ZO-2 in organizing the actin cytoskeleton may not only be 
critical for the formation of TJs, but also for cell migration. ZO-1 interacts thorugh its C-
terminus with actin directly and indirectly via the actin binding protein 4.1 (Itoh et al. 
1997; Fanning et al. 1998; Mattagajasingh et al., 2000). Futhermore, the N-terminus of 
ZO-1 can mediate associations with the E-cadherin/alpha, β-catenin complex (Itoh et al. 
1997), which plays a critical role in cell migration (refs).  ZO-2 can also interact with F-
actin directly (Wittchen et al. 1999) or indirectly via protein 4.1 (Mattagajasingh et al. 
2000). Furthermore, given the severe effect of the lack of ZO-1 on TJs, the proper 
distribution of membrane proteins important for adhesion such as integrins and cadherins 






Chapter 11 Generation and phenotypic analysis 
of ZO-2-/-ZO-3-/- embryonic stem cells 
11.1 Isolation of ZO-3-/- ES cells 
      To obtain ZO3-/- ES cells, 129Sv ZO-3-/- male and female mice were mated, E3.5 
blastocysts collected from uteri of the pregnant mice and cultured for 4 days. Individual 
colonies were dissociated and inner mass cells with ES cell morphology derived as 
described in Materials and Methods (Chapter 2). Using this approach, two independent 
ZO-3 null ES cell clones were isolated from the inner cell mass. ZO-3-/- ES cells were 
differentiated into EBs and the expression level and localization of TJ and AJ markers 






Figure 56 Expression levels of ZO proteins and TJ and AJ markers in ZO-3-/- EBs. As 
expected, ZO-3 is not expressed in ZO-3-/- EBs. The expression levels of ZO-1, ZO-2, and 








Figure 57 ZO protein expressions in ZO-3-/- EBs. (A) ZO-3 is not expressed in ZO-3-/- 






11.2 Generation of ZO-2-/-ZO-3-/- ES cells 
      The floxed Neo gene in the ZO-3 mutant allele was removed by transfecting 
individual ZO-3-/- ES cells with a plasmid encoding cre recombinase (Taniguchi et al. 
1998). Cells carrying the plasmid were selected with puromycin and surviving clones 
tested for sensitivity to G418, indicating excision of the Neo gene. Clones sensitive to 
G418 were amplified, tested for their sensitivity to puromycin to identify clones that had 
lost the cre plasmid, and transfected with the ZO-2 targeting vector. ZO-2 knockout was 
then achieved in the ZO-3-/- ES cell line as described in Chapter 9 for the inactivation of 
ZO-2. Inactivation of the ZO-2 and ZO-3 gene was confirmed by Western blot (Figure 
58A) and five independent ZO-2-/-ZO-3-/- ES cell clones were identified from the 
screening. All these double knockout ES cells did not show any morphological 









Figure 58 Characterization of ZO-2-/-ZO-3-/- ES cells. (A) ZO protein expression in 
ZO-2-/-ZO-3-/- ES cells. ZO-2 and ZO-3 are not expressed in the double knockout ES 
cells. The expression of ZO-1 is not obviously altered. (B) ZO-2-/-ZO-3-/- ES cells have a 












11.3 The expression levels of TJ and AJ markers are not 
altered in ZO-2-/-ZO-3-/- EBs. 
      Given the strong expression of ZO-2 and ZO-3 proteins in EBs, the expression levels 
of different tight junction and adherens junction markers in ZO-2-/-ZO3-/- EBs were 
analyzed by Western blot. As expected, no ZO-2 and ZO-3 was detected in ZO-2-/-ZO-3 
-/- EBs (Figure 59). The expression levels of ZO-1, occludin, cingulin, E-cadherin and 
claudin-3 were not significantly differenent between WT, ZO-2-/-, ZO-3-/- and ZO-2-/-
ZO-3-/- EBs (Figure 59).  
 
Figure 59 Expression levels of ZO proteins and TJ and AJ markers ZO-2-/-ZO-3-/- 
EBs. ZO-2 and ZO-3 are not expressed in ZO-2-/-ZO-3-/- EBs. The expression levels of 
ZO-1, TJ and AJ markers are not altered in ZO-2-/-ZO-3-/- EBs. 
 
 154
11.4 The localization of TJ and AJ markers is not altered in 
ZO-2-/-ZO-3-/- EBs. 
      Given the role of ZO-2 and ZO-3 as scaffold proteins that localize proteins to TJs we 
analyzed by immunostaining if the subcellular distribution of selected TJ markers was 
affected. As expected, no specific ZO-2 and ZO-3 staining was found in ZO-2-/-ZO-3-/- 
EBs (Figure 60A, B). ZO-1, occludin, cingulin and claudin-6 were all well localized to 
TJs in ZO-2-/-ZO-3-/- EBs (Figure 60C, D, E, F). Furthermore, the localization of the 
apical marker moesin and the lateral marker E-cadherin was unchanged in ZO-2-/-ZO-3 
-/- EBs (Figure 61), indicating that the ability of TJs to maintain the asymmetric 
distribution of membrane proteins to the apical and basolateral domains was unaffected 
when both ZO-2 and ZO-3 were knocked out.  
 The structural integrity and permeability barrier function of TJs in ZO-2-/-ZO-3-/- 















Figure 60 Distribution of ZO proteins, TJ and AJ markers in ZO-2-/-ZO-3 EBs. (A, B) 
ZO-2 and ZO-3 are not expressed in ZO-2-/-ZO-3-/- EBs. (C, D, E, F) The localization of 






Figure 61 Apical-basolateral polarity is not affected in ZO-2-/-ZO-3-/- EBs. The apical 




ZO-2-/-ZO-3-/- ES cells were generated to determine if the absence of both ZO 
proteins had an effect on the formation of functional TJs in EBs. In ZO-2-/-ZO-3-/- EBs, 
the protein expression levels and localization of various TJ and AJ markers analyzed 
were not affected. The apical-basal polarity of the epithelial cells was maintained. Our 
findings are thus consistent with a recent report that visceral endoderm epithelial-like 
ZO-3-/- cells retain a normal molecular TJ architecture even when ZO-2 expression is 
suppressed (Adachi et al. 2006). Therefore, at least in EBs cultured in vitro, ZO-2 and 
ZO-3 are dispensable for the formation of functional TJs. However, similar to ZO-2-/- 
embryos, embryos lacking both ZO proteins apparently died after implantation (see 
Chapter 7). As discussed above, a similar difference was observed between ZO-2-/- EBs 
and embryos and may be attributed to physiological stress during embryo growth in the in 
vivo environment.  
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Chapter 12 Summary and perspectives 
TJs are critical components of epithelia and endothelia, where they are involved in 
maintaining apical basal cell polarity, the formation of protective barriers and the 
selective exchange of solutes between different tissue compartments. Deregulation of TJ 
function has been associated with many pathological conditions and several components 
of TJ act as receptors for pathogens (Sawada et al., 2003). Members of the ZO protein 
family were among the first TJ proteins to be identified and have been extensively 
characterized (González-Mariscal et al. 2000, 2003; Köhler et al., 2005; Matter et al., 
2003, 2007). As scaffolding proteins, ZO proteins engage in multiple protein-protein 
interactions. ZO not only link transmembrane TJ proteins to the actin cytoskeleton, but 
recent evidence points to a central role for ZO proteins in organizing signaling networks 
that regulate, possibly in response to the cell-cell contact, vesicle trafficking, gene 
expression, and cell proliferation and differentiation (González-Mariscal et al. 2000, 
2003; Köhler et al., 2005; Matter et al., 2003, 2007). Interestingly, ZO proteins are not 
restricted to TJs in epithelia or endothelia, but are also found in TJs or TJ-like structures 
formed by other cell types such as Schwann cells (Poliak et al., 2002) and cadiomyocytes 
(Borrmann et al., 2006), as well as in AJs (Ikenouchi et al., 2007) and gap junctions 
(Segretain et al., 2004; Hunter et al., 2005; Laing et al., 2005). 
One intriguing question is the relevance for three closely related ZO genes in 
mammals. At the beginning of this work, it was thought that ZO proteins show a high 
degree of redundancy, a notion based on the silencing of ZO protein expression, either 
individually or in combination, in different cell lines (Medina et al., 2000; Umeda et al., 
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2004, 2006; Adachi et al. 2006; McNeil et al., 2006; Hernandez et al., 2007). Although 
sometimes conflicting, these results strongly suggested that individual ZO proteins may 
be largely dispensable for TJ structure and/or function. In the course of my studies, this 
idea was reinforced by the lack of a phenotype for a mouse carrying an inactivated ZO-3 
gene.  
To address the role of different ZO-proteins in a more physiological context, I 
generated mice in which ZO protein genes were inactivated by homologous 
recombination, either individually or in combination. The finding that mice lacking ZO-1 
or ZO-2, but not ZO-3, shows early embryonic lethality have clearly established non-
redundant roles for these proteins. Furthermore, this is to my knowledge the first time 
that ZO proteins have been shown to be critical for mammalian development. 
Furthermore, I was able to rescue the embryonic lethality of ZO-2 null mice by 
generating ZO-chimera, which revealed interesting phenotypes in the testis, kidney and 
the inner ear, establishing unique functions for ZO-2 in different tissues of adult mice. 
As an alternative to the characterization of ZO proteins in transgenic mice, I 
generated ES cells lacking one or several ZO proteins. This approach has allowed me to 
compare different properties and functions of TJs lacking ZO proteins in an in vivo and 
an in vitro system. Among the 3 ZO proteins, the loss of ZO-1 showed the most severe 
effect on TJ structure. Surprisingly, ZO-2 was important for TJ structure and possibly 
barrier function in vivo, but not in EBs in vtiro. This finding indicates that under 
physiological stress or perhaps depending on cell type, the absence of a particular protein 
may have a more profound effect on TJ structure/function. This could, to some extent, 
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also explain the conflicting results reported in the literature for the silencing of ZO 
protein expression in different tissue culture cell types. 
My work has also opened several interesting venues for future work. First, it will be 
of interest to analyze in further detail the embryonic lethality associated with the lack of 
ZO-1. Second, characterization of the phenotypes observed for the ZO-2 chimera and the 
generation of conditional ZO-2 (and ZO-1) knock-out mice will establish distinct 
functions for these proteins in different tissues of the adult animal. Third, it will be 
important to determine where for extraembryonic development ZO-2 is important. Forth, 
the lack of either ZO-1 or ZO-2 results in enlarged EBs, suggesting that either 
proliferation and/or apoptosis are affected. Fifth, the observation that the absence of ZO-1 
promotes mesoderm formation indicates that individual ZO proteins may be involved in 
cell lineage determination during development. The availability of ES cells lacking ZO 
proteins will allow researchers to address the requirement of individual ZO proteins for 
the differentiation of ES cells into specific cell lineages. Finally, the fundamental 
question if a phenotype associated with the lack of a ZO protein is due to the loss of 
transmembrane TJ protein and cytoskeleton tethering, or the disruption of signaling 
networks organized by these scaffolding proteins, will need to be addressed. 
 In conclusion, my work has established critical and non-redundant roles for 
individual ZO proteins in early development of mammals. Furthrmore, it has unraveled 
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